Stockwinners Market Radar for November 28, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

IXHL

Hot Stocks

19:50 EST IXHL Stock trading halted, news pending
PRAX

Hot Stocks

19:50 EST Praxis Precision Medicines trading halted, news pending
MSFT

Hot Stocks

19:45 EST Microsoft maintains quarterly dividend of 75c per share - The dividend is payable March 14, 2024, to shareholders of record on Feb. 15, 2024.
AMGN

Hot Stocks

19:19 EST Amgen receives Orphan Drug Designation for treatment of biliary tract cancers - Amgen's treatment of biliary tract cancers was granted orphan status by the FDA, according to a post to the agency's website. Reference Link
DOW

Hot Stocks

18:44 EST Dow Inc. CEO: China is still strong for us and coming back - In an interview on CNBC's Mad Money, Jim Fitterling said Dow saw the third consecutive quarter of volume increases in Q3. "The dividend is safe and the balance sheet is the best it has been for some time," he noted.
IONM

Hot Stocks

18:32 EST Assure Holdings receives non-compliance letter from Nasdaq - Assure Holdings announced that on November 21 it received a notice from the Nasdaq Stock Market indicating that as a result of the delinquency in the timely filing of the Company's quarterly report on Form 10-Q for the period ended September 30, the Company is out of compliance with Nasdaq Listing Rule 5250, which requires listed companies to timely file all required periodic reports with the SEC. The Notice has no immediate effect on the listing or trading of the Company's common stock on the Nasdaq Capital Market. The Notice provides that the Company has 60 calendar days from the date of the Notice, or January 22, 2024, to submit a plan to regain compliance with Nasdaq Listing Rule 525. The Company continues to work diligently to complete the 10-Q and expects to file the 10-Q prior to January 22, 2024, which would eliminate the need for the Company to submit to Nasdaq a formal plan to regain compliance with the Listing Rule.
MKC

Hot Stocks

18:23 EST McCormick raises quarterly dividend to 42c from 39c per share - The dividend is payable January 8, 2024 to shareholders of record December 29, 2023. This marks the 38th consecutive year that the company has increased its quarterly dividend.
CFFN

Hot Stocks

18:14 EST Capitol Federal director buys $104K in common stock - In a regulatory filing, Capitol Federal disclosed that its director Carlton Ricketts bought 20K shares of common stock on October 27th in a total transaction size of $104K. Shares of Capitol Federal are up 4.5% afterhours at $5.57.
OMEX

Hot Stocks

18:07 EST Odyssey Marine receives non-compliance letter from Nasdaq - Odyssey Marine Exploration reported that on November 21, Odyssey received a notice from Nasdaq Regulation that Odyssey is not in compliance with Nasdaq Rule 5250 because it had not yet filed its Form 10-Q for the period ended September 30, 2023 with the SEC. Odyssey plans to regain compliance with Nasdaq Rule 5250 by filing the Form 10-Q with the SEC, which it expects to do as soon as practicable.
SNBR

Hot Stocks

18:02 EST Sleep Number falls 6% to $8.83 after being replaced in S&P SmallCap 600 index
ABCL

Hot Stocks

18:00 EST AbCellera has $1B + in liquidity to execute on strategy beyond next 3 years - Information provided in company 8k filing.
ABCL

Hot Stocks

17:57 EST AbCellera announces reorganization, reduction in workforce - On November 28, AbCellera Biologics announced a reorganization and associated reduction in its workforce to better focus its efforts towards the clinical development of new antibody medicines for patients.The reorganization is consistent with long-term plans to prioritize strategic partnerships and internal drug development, and to increase operational efficiency across the business. The workforce reduction impacts approximately ten, 10% percent of the company's workforce. The Company estimates that it will incur approximately $2.5M in cash expense in connection with the workforce reduction. With over $1B billion in available liquidity, AbCellera has sufficient capital to execute on its strategy beyond the next 3 years. Information provided obtained from company 8K filing.
RIO

Hot Stocks

17:51 EST Star Diamond to acquire Rio Tinto's 75% interest in Fort a la Corne project - Star Diamond Corporation announced that it has entered into a binding agreement with Rio Tinto Exploration Canada, providing for the transfer by RTEC to Star Diamond of all of RTEC's 75% interest in the Fort a la Corne diamond project located in central Saskatchewan. The Agreement provides that, upon closing: RTEC will transfer to Star Diamond all of RTEC's 75% interest in the Project, such that the Project will be 100% owned by Star Diamond; RTEC will transfer to Star Diamond ownership of the trench cutter drill rig used by RTEC to complete its prior bulk sampling program at the Project; RTEC will transfer to Star Diamond the Bulk Sample Plant located at the Project, including the TOMRA XRT diamond sorting machine that is on-site; Star Diamond will issue to RTEC and/or an affiliate that number of common shares of Star Diamond that results in RTEC and its affiliates owning 19.9% of the then outstanding common shares of Star Diamond (RTEC and its affiliates currently own approximately 2.3% of Star Diamond's outstanding common shares); and RTEC and Star Diamond will enter into an Investor Rights Agreement whereby, among other things, RTEC will be granted certain pre-emptive rights to maintain its 19.9% ownership interest in Star Diamond in connection with future financings undertaken by Star Diamond, and RTEC will agree to certain standstill protections provided that RTEC will have the right to increase its 19.9% ownership position in the event that Star Diamond receives an acquisition proposal. "Acquiring 100% ownership of the Project will be a major accomplishment for Star Diamond and its shareholders. We are grateful to Rio Tinto for the significant monetary investment and expertise it has contributed to the Project over the past more than five years, which has meaningfully advanced what Star Diamond believes is one of the most promising diamond projects in the world," said Ewan Mason, President and Chief Executive Officer of Star Diamond. Upon completion of the transactions that are the subject of the Agreement, Star Diamond will have full control and responsibility for the Project, the existing joint venture agreement between RTEC and Star Diamond will terminate, and Star Diamond will release and indemnify RTEC for liabilities arising from or relating to the Project, all in exchange for a Cdn. $4 million payment from RTEC to Star Diamond. RTEC has agreed that it will provide on Star Diamond's behalf, for up to five years following closing, letters of credit in the aggregate amount of no more than Cdn. $9.9 million to secure certain environmental remediation and reclamation obligations related to the Project. Star Diamond will be obliged to repay any amounts drawn on these letters of credit and such repayment obligations will be secured against the Project and its assets.
DNMR

Hot Stocks

17:44 EST Danimer Scientific director buys $93.4K in common stock - In a regulatory filing, Danimer Scientific disclosed that its director Richard Hendrix bought 28.5K shares of common stock on November 28th in a total transaction size of $93.4K.
NOC

Hot Stocks

17:38 EST Northrop Grumman subsidiary awarded $235.7M Navy contract - Alliant Techsystems Operations, a wholly owned subsidiary of Northrop Grumman, was awarded a $235.7M firm-fixed-price contract. This contract provides for the production and delivery of 118 low rate initial production Lot Three AGM-88G Advanced Anti-Radiation Guided Missiles - Extended Range to include 84 AGM-88G AARGM-ER All Up Rounds, or AURs, for the Navy; 34 AGM-88G AARGM-ER AURs for the Air Force; six AGM-88G AARGM-ER Captive Air Training Missiles; eight Telemetry/Flight Termination System kits for the Navy, ten dummy air training missiles for the Air Force, as well as initial spares, special tooling and test equipment kits, and associated supplies and support. Work is expected to be completed in February 2027. Fiscal 2023 weapons procurement funds in the amount of $167.43M; fiscal 2023 missile procurement funds in the amount of $68.25M and fiscal 2022 weapons procurement funds in the amount of $15,549 will be obligated at time of award, $15,549 of which will expire at the end of the current fiscal year. This contract was not competitively procured pursuant to 10 U.S. Code 3204. Naval Air Systems Command is the contracting activity.
WDAY

Hot Stocks

17:35 EST Workday jumps 6% to $253.20 after Q3 results beat estimates
DUET

Hot Stocks

17:28 EST DUET Acquisition and Fenix 360 announce combination agreement - Fenix 360 Pte, a global social media company, and DUET Acquisition announced that that they have entered into a business combination agreement, pursuant to which DUET will acquire 100% of the outstanding equity interests of FENIX360. The Transaction is expected to be completed in the first half of 2024, subject to regulatory approvals and other customary closing conditions. The Transaction values FENIX360 at a $610M enterprise value.
BIP

Hot Stocks

17:26 EST TSX accepts Brookfield Infrastructure's renewal of its normal course issuer bid - Brookfield Infrastructure Partners announced that the Toronto Stock Exchange, or TSX, accepted a notice filed by BIP of its intention to renew its normal course issuer bid for its outstanding limited partnership units and its cumulative class A preferred limited partnership units. Brookfield Infrastructure Corporation, or BIPC, also announced that the TSX accepted a notice filed by BIPC of its intention to renew its normal course issuer bid for its outstanding class A exchangeable subordinate voting shares. BIP and BIPC believe that if the trading price of Units or Exchangeable Shares, respectively, does not fully reflect their value, the acquisition of Units or Exchangeable Shares, as applicable, may represent an attractive use of available funds. Under BIP's normal course issuer bid, the Board of Directors of the general partner of BIP authorized BIP to repurchase up to 5% of the issued and outstanding LP Units, or up to 23,107,234 LP Units. At the close of business on November 21, there were 462,144,684 LP Units issued and outstanding. Under BIP's normal course issuer bid, it may repurchase up to 100,061 LP Units on the TSX during any trading day, which represents 25% of the average daily trading volume of 400,244 LP Units on the TSX for the six months ended October 31 calculated in accordance with the rules of the TSX.
BA

Hot Stocks

17:22 EST Boeing awarded $2.33B Air Force contract modification - Boeing has been awarded a $2.33B modification to a previously awarded contract for 15 KC-46A Air Force Production Lot 10 aircraft. Work will be performed in Seattle, Washington, and is expected to be completed by July 31, 2027. Fiscal 2024 aircraft procurement funds in the amount of $2.33B are being obligated at time of award. The Air Force Life Cycle Management Center is the contracting activity.
FLNC

Hot Stocks

17:22 EST Fluence Energy jumps 13% to $23.00 after Q4 earnings beat
WS...

Hot Stocks

17:21 EST Worthington Steel to be added to S&P 600 at open on 12/1 - Worthington Steel (WS) will be added to the S&P SmallCap 600 effective prior to the open of trading on Friday, December 1, replacing Sleep Number (SNBR) which will be removed from the S&P SmallCap 600 effective before the open of trading on Monday, December 4. Worthington Industries (WOR) is spinning off Worthington Steel in a transaction expected to be completed on December 1. Post spin-off, the parent Worthington Industries will remain in the S&P SmallCap 600 and will change its name to Worthington Enterprises.
OLMA

Hot Stocks

17:19 EST Olema Oncology to present new Palazestrant clinical data at SABCS - Olema Pharmaceuticals "announced that it will be presenting new Phase 1b/2 clinical data of palazestrant (OP-1250) in combination with CDK4/6 inhibitor ribociclib, a Poster Spotlight Session on Phase 2 clinical data of palazestrant in combination with palbociclib, and a trial-in-progress poster for the OPERA-01 monotherapy Phase 3 pivotal trial at the upcoming San Antonio Breast Cancer Symposium, or SABCS, being held December 5-9, 2023, at the Henry B. Gonzalez Convention Center in San Antonio, Texas. "
ARVN PFE

Hot Stocks

17:07 EST Arvinas, Pfizer announce updated Vepdegestrant data to be presented at SABCS - Arvinas (ARVN) and Pfizer (PFE) announced that updated clinical trial data for vepdegestrant (ARV-471) will be presented at the 2023 San Antonio Breast Cancer Symposium (SABCS). Vepdegestrant is a novel oral PROteolysis TArgeting Chimera estrogen receptor (ER) degrader currently being investigated for the potential treatment of patients with locally advanced or metastatic estrogen receptor (ER) positive/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer. Arvinas and Pfizer are collaborating to develop and commercialize vepdegestrant. Data from the Phase 1b study assessing vepdegestrant in combination with palbociclib will be presented in a spotlight session on December 7, 2023. An update on the Phase 2 vepdegestrant monotherapy (VERITAC) study will be presented in a poster presentation alongside four other posters during the symposium held from December 5-9, 2023, in San Antonio, Texas.
GOOG GOOGL

Hot Stocks

17:07 EST YouTube debuts features including AI experiments for eligible Premium members - In an earlier release, You Tube blogged in part: "For a limited time, eligible Premium members can try out new features that we're working on, including AI experiments. As a Premium member, you'll also enjoy watching YT ad-free, downloads, and more. As a Premium member, you'll also enjoy watching YT ad-free, downloads, and more...Ask questions, get AI-powered answers...Available until Dec 15...This experiment uses conversational AI to answer questions about videos you're watching, recommend content, and help you learn - all without interrupting playback...Play games instantly with no downloads...Find a "Playables" shelf by scrolling on Home or through a "Playables" link in the Explore menu on desktop and mobile...Explore comment topics summarized by AI...Available until Dec 5..This experiment uses AI to organize and summarize published comments on videos with large comment sections.And..Give Your Feedback, Get Rewarded...We want to know your thoughts about YouTube and other Google products so we can keep improving them." Reference Link
FTCH

Hot Stocks

17:03 EST Farfetch will not announce Q3 results - Farfetch will not announce its third quarter 2023 financial results and will not hold its related conference call previously scheduled for Wednesday, November 29. The company expects to provide a market update in due course. The company will not be providing any forecasts or guidance at this time, and any prior forecasts or guidance should no longer be relied upon.
SMBK

Hot Stocks

17:02 EST SmartFinancial transfers listing of its common stock to the NYSE - SmartFinancial, the parent company for SmartBank, announced that it is transferring the listing of its common stock to the New York Stock Exchange from The Nasdaq Stock Market. SmartFinancial's common stock is expected to begin trading on the NYSE on Monday, December 11, under the ticker symbol of "SMBK". SmartFinancial expects its common stock to continue to trade on Nasdaq until the close of the market on December 08.
CFIV

Hot Stocks

17:01 EST CF Acquisition Corp. IV to redeem all its outstanding shares - CF Acquisition Corp. IV announced that its board of directors has determined to redeem all of its outstanding shares of Class A common stock, par value $0.0001 per share, sold in its initial public offering because CF IV is unlikely to be able to complete an initial business combination by the deadline under its Amended and Restated Certificate of Incorporation, as amended. Accordingly, CF IV will not make the next $150,000 monthly installment due by November 28 to its trust account in connection with the extension of its time to consummate an initial business combination previously approved by its stockholders in June 2023 and instead CF IV will cease all operations except for the purpose of winding up, as promptly as reasonably possible, redeem the public shares at a per-share price, payable in cash, equal to the aggregate amount then on deposit in its trust account, including interest earned on the funds held in the trust account and not released to CF IV to pay its taxes, divided by the number of outstanding public shares, which redemption will completely extinguish rights of the holders of the public shares as stockholders, subject to applicable law, and as promptly as reasonably possible following the Redemption, subject to the approval of CF IV's remaining stockholders, dissolve and liquidate, subject in each case to its obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. Trust Company, as its trustee, to take all necessary actions to effect the Redemption. The proceeds thereof, less $100,000 of interest to pay dissolution expenses and net of taxes payable, will be held in a trust operating account while awaiting disbursement to the holders of the public shares. CF IV expects to redeem all of the outstanding public shares for an estimated redemption price of approximately $10.57 per share. All other costs and expenses associated with implementing the dissolution will be funded from proceeds held outside of the Trust Account. CF IV expects that the Nasdaq Stock Market LLC will file a Form 25 with the SEC to delist its securities after the last day of trading on December 7.
APP

Hot Stocks

16:57 EST AppLovin CMO sells $2.05M in common stock - In a regulatory filing, AppLovin disclosed that its CMO Katie Jansen sold 52.2K shares of common stock on November 28th in a total transaction size of $2.05M.
SOLO

Hot Stocks

16:55 EST ElectraMeccanica, Tevva resolve merger litigation - ElectraMeccanica Vehicles announced the amicable resolution of litigation with Tevva Motors Limited relating to the termination of the previously-announced arrangement agreement, dated August 14, 2023, by and among the parties. The parties' agreement resolves Tevva's claims against ElectraMeccanica, 1432952 B.C. Ltd., 1432957 B.C. Ltd. and Susan E. Docherty, ElectraMeccanica's Chief Executive Officer and Interim Chief Operating Officer, as well as counterclaims that ElectraMeccanica was prepared to file against Tevva and others in relation to the original arrangement agreement. ElectraMeccanica and Tevva agreed that it was in their mutual best interests to resolve any litigation relating to the arrangement agreement with no attribution or admission of wrongdoing by any party. The parties further believe that they are best served by moving forward as independent companies with their respective business models. ElectraMeccanica and Tevva will continue to pursue their respective futures as leaders and innovators in the growing electrification market. ElectraMeccanica believes that it remains well-capitalized and intends to continue exploring other strategic third-party opportunities and potential options for its business.
OTEX

Hot Stocks

16:45 EST OpenText trading resumes
JBL

Hot Stocks

16:39 EST Jabil falls 10% to $118.00 after cutting Q1 revenue outlook - The company's Q2 revenue guidance also came in below analysts' consensus estimates.
LESL

Hot Stocks

16:33 EST Leslie's falls 16% to $4.90 after Q4 earnings miss, below-consensus FY24 guide
NYXH

Hot Stocks

16:32 EST Nyxoah appoints rancis Kim as chief regulatory and quality officer - Nyxoah announced the appointment of Francis Kim as chief regulatory and quality officer. Francis will be leading Nyxoah's global regulatory and quality departments. Kim is a global regulatory and quality executive in the healthcare industry, having spent more than 25 years in the medical device and life sciences sector.
NTAP

Hot Stocks

16:31 EST NetApp jumps 9% to $85.26 after Q2 earnings beat, FY24 guidance raise
PUMP

Hot Stocks

16:30 EST ProPetro names Shelby Fietz CCO, Celina Davila CAO - ProPetro Holding Corp. announced that it has appointed Shelby Fietz as its Chief Commercial Officer and Celina Davila as its Chief Accounting Officer, effective November 26, 2023. Sam Sledge, Chief Executive Officer, said, "I'm pleased to announce Shelby Fietz's promotion to Chief Commercial Officer of ProPetro. With over a decade of experience here at ProPetro, Shelby has been instrumental in leading our commercial execution and maintaining key customer relationships. His expertise is crucial as our industry evolves towards an industrial model, necessitating sophisticated multi-service arrangements for our consolidating customer base. Shelby's deep understanding of our customers and of our own unique capabilities has been and will continue to be pivotal in effectively implementing our commercial initiatives and ensuring we deliver our services in innovative ways that align with our strategy and drive industry-leading efficiencies in our customer's completion programs. We are confident that Shelby's leadership will continue to bring significant value to ProPetro." David Schorlemer, Chief Financial Officer, said, "We are pleased to appoint Celina Davila to her new position as Chief Accounting Officer. Effective immediately, she will act as the Company's principal accounting officer. Celina brings significant experience in our business with ProPetro and in her previous roles at Pioneer Natural Resources and in public accounting. She also has been instrumental in building and leading our accounting organization. Her focus on innovation is driving continued enhancement in our business processes and creating accounting and financial reporting efficiencies. I'm delighted to be working with Celina in her new role."
COIN

Hot Stocks

16:28 EST Coinbase officer Brock sells over $1.8M in company shares - Lawrence Brock, an officer of Coinbase, disclosed in a regulatory filing the sale of 16,075 shares of company stock at $113.99 per share on November 24 for a total transaction amount of $1,832,462.
CPTK

Hot Stocks

16:23 EST Crown PropTech Acquisitions receives NYSE notice for 10-Q on timely filing - Crown PropTech Acquisitions, a Cayman Islands exempted company announced that it received a notice from the New York Stock Exchange on November 21 indicating that the Company is not in compliance with Section 802.01E of the NYSE Listed Company Manual as a result of its failure to timely file its Quarterly Report on Form 10-Q for the quarter ended September 30 with the Securities and Exchange Commission . The NYSE informed the Company that, under NYSE rules, the Company will have six months from November 20 to file the Form 10-Q with the SEC. The Company can regain compliance with the NYSE listing standards at any time prior to that date by filing its Form 10-Q. If the Company fails to file the Form 10-Q before the NYSE's compliance deadline, the NYSE may grant, at its sole discretion, an extension of up to six additional months for the Company to regain compliance.
VCXB

Hot Stocks

16:22 EST 10X Capital Venture Acquisition III gets NYSE letter for 10-Q timely filing - 10X Capital Venture Acquisition announced that New York Stock Exchange Regulation by letter dated November 21 notified 10X III that it was not in compliance with the NYSE American continued listing standards because 10X III did not timely file its Quarterly Report on Form 10-Q for the quarter ended September 30 which was due on November 20. As reported in the Form 12b-25 filed by 10X III with the Securities and Exchange Commission on November 14 10X III's independent registered public accounting firm was still in the process of completing the review of the financial statements for the quarter ended September 30 and required additional time to complete its review of such financial statements.
FUV

Hot Stocks

16:18 EST Arcimoto gets Nasdaq notice on timely filing of 10-Q - Arcimoto announced that on November 22, it received a notice from The Nasdaq Stock Market stating that because the Company has not yet filed its quarterly report on Form 10-Q for the period ended September 30 the the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission.The current notice will have no immediate effect on the listing or trading of the Company's common stock on the Nasdaq Global Market, although there can be no assurances that further delays in the filing of the Form 10-Q will not have an impact on the listing or trading of the Company's common stock. Nasdaq indicated that the Company must: (i) no later than January 22 , submit a plan to regain compliance with respect to the filing requirement; and (ii) on or before May 20, file the delinquent Form10-Q. The Company intends to file the delinquent Form 10-Q as soon as practicable.
PSNL

Hot Stocks

16:17 EST Personalis, Tempus enter into strategic collaboration over cancer testing - Personalis and Tempus Labs announced a strategic collaboration to co-commercialize NeXT Personal Dx, Personalis' whole genome-based liquid biopsy laboratory developed test for detection of molecular residual disease and recurrence in cancer. NeXT Personal Dx is a leap forward in tumor-informed approaches, setting the new standard in performance of MRD tests with unprecedented sensitivity and high specificity. The test was launched by Personalis in October of this year. The two companies will work together exclusively in tumor-informed MRD testing for lung cancer, as well as breast cancer and immunotherapy monitoring after clinical validation of NeXT Personal Dx in those indications. The agreement contemplates testing up to tens of thousands of new patients over the next three years. "A core part of our 'Win in MRD' strategy has been to partner with a top oncology testing company with a leading sales channel to co-commercialize NeXT Personal Dx," said Chris Hall, President and CEO of Personalis. "With today's announcement, we have fulfilled that part of our strategy and we are excited about starting the journey together with Tempus to bring our NeXT Personal Dx test to the country's oncologists and their patients."
OTEX

Hot Stocks

16:17 EST OpenText to divest AMC business to Rocket Software for $2.275B in cash - Open Text announced that it has reached a definitive agreement to divest its AMC business to Rocket Software, a Bain Capital portfolio company, for $2.275B in cash. OpenText's AMC business provides market leading mainframe modernization and connectivity software to more than 10,000 customers enabling them to run mission-critical business applications in hybrid cloud environments. About the Transaction: $2.275B all-cash purchase price before taxes and fees; Sale price of 4.6x AMC's F'23 revenue of approximately $500M; Sale price of 8.3x AMC's F'23 Adjusted EBITDA of approximately $275M; Net proceeds to reduce debt, to be applied to the Acquisition Term Loan and Term Loan B; Expect to close in OpenText's fourth fiscal quarter ending June 30, 2024, subject to regulatory approvals and customary closing conditions. The combination of AMC and Rocket Software's highly complementary product portfolios will create one of the world's largest IT and mainframe modernization and connectivity software companies. Under the terms of the agreement, the software, associated services, and approximately 750 employees of AMC will be integrated into Rocket Software. Until closing, OpenText and Rocket Software will continue to constructively collaborate to protect customer investments and expand offerings for joint customers.
FSRX

Hot Stocks

16:17 EST FinServ Acquisition Corp. II announces intention to liquidate - FinServ Acquisition Corp. II announced that the board of directors of FinServ II determined FinServ II cannot complete a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses by February 22, 2024, the deadline by which FinServ II has to consummate such business combination under its amended and restated certificate of incorporation. Consequently, the board determined the company will, as of November 22, cease all operations except for the purpose of winding up as soon as practicable, as promptly as reasonably possible redeem the shares of its Class A common stock that were included in the units issued in FinServ II's initial public offering at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account established in connection with the IPO including interest earned on the funds held in the trust account and not previously released to FinServ II to pay its taxes, divided by the number of outstanding public shares, which redemption will completely extinguish public stockholders' rights as stockholders, subject to applicable law and as promptly as reasonably possible following the redemption, subject to the approval of FinServ II's remaining stockholders, liquidate the funds held in the trust account and dissolve FinServ II, subject in each case to its obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to FinServ II's warrants, which will expire worthless. FinServ Holdings II, LLC, FinServ II's sponsor, has agreed to waive its redemption rights with respect to the shares of FinServ II's Class B common stock issued prior to the IPO, including shares of FinServ II's Class A common stock issued upon conversion of such Class B common stock.
SFNC

Hot Stocks

16:16 EST Simmons First National appoints Daniel Hobbs as CFO - Simmons First National announced Daniel Hobbs will join the company as executive vice president and CFO, effective December 4. He will report to Simmons president Jay Brogdon and will be based in Little Rock, Arkansas. Prior to Hobbs arrival, Brogdon served as both President and CFO. Hobbs brings extensive experience in the financial services industry, with a long, successful track record of execution and results. He most recently served as executive vice president and head of finance for a Southeastern bank with more than $150B in assets, leading a finance team that provided financial leadership for all aspects of the bank's lines of business - consumer, corporate and wealth - as well as support groups, strategic insights and analytics, and financial systems. He also served as a key member of the senior leadership team that developed strategies designed to drive growth, improve efficiency and navigate the current economic and operating environment. Hobbs is a graduate of the University of Alabama at Birmingham where he earned a Bachelor of Science degree in accounting. He graduated with honors from the CBA Executive Banking School and serves as a faculty member helping top talent from banks across the country and abroad to learn banking from the CFO perspective.
CPTK

Hot Stocks

16:14 EST Crown PropTech Acquisitions receives NYSE notice for 10-Q t on timely filing - Crown PropTech Acquisitions, a Cayman Islands exempted company announced that it received a notice from the New York Stock Exchange on November 21 indicating that the Company is not in compliance with Section 802.01E of the NYSE Listed Company Manual as a result of its failure to timely file its Quarterly Report on Form 10-Q for the quarter ended September 30 with the Securities and Exchange Commission . The NYSE informed the Company that, under NYSE rules, the Company will have six months from November 20 to file the Form 10-Q with the SEC. The Company can regain compliance with the NYSE listing standards at any time prior to that date by filing its Form 10-Q. If the Company fails to file the Form 10-Q before the NYSE's compliance deadline, the NYSE may grant, at its sole discretion, an extension of up to six additional months for the Company to regain compliance, depending on
HPE

Hot Stocks

16:14 EST HP Enterprise reports Q4 ARR up 39% from last year at $1.3B - Reports Q4 Annualized revenue run-rate of $1.3 billion, up 39% from the prior-year period and 37% in constant currency.
OTEX

Hot Stocks

16:14 EST OpenText trading halted, news pending
TRIB

Hot Stocks

16:11 EST Trinity Biotech receives MVPHS requirement notice from Nasdaq - Trinity Biotech announced that on November 21 the Company received notice from the Nasdaq Stock Market that the Company is not in compliance with the minimum market value of publicly held shares MVPHS requirement set forth in the Nasdaq Listing Rules. For continued listing on the Nasdaq Global Select Market, registrants are required to maintain a minimum MVPHS of US$15M in accordance with Nasdaq Listing Rule 5450(b)(3)(c). Nasdaq Listing Rule 5810(c)(3)(D) provides that the failure to meet the minimum MVPHS requirement exists if the deficiency continues for a period of 30 consecutive business days. The Company intends to monitor its MVPHS between now and May 20, and intends to cure the deficiency within the prescribed grace period. During this time, the Company expects that the ADSs of the Company will continue to be listed and trade on the Nasdaq Global Market. The Company's management is evaluating various options available to regain compliance and maintain its continued listing. The Company's business operations are not affected by the Notification Letter.
TXT

Hot Stocks

16:10 EST Textron announces 2% global workforce reduction - In a regulatory filing, Textron said, "On November 28, 2023, the Board of Directors of Textron approved a restructuring plan developed by management in connection with the company's annual operating plan process. The plan will reduce operating expenses through headcount reductions at the Industrial, Bell and Textron Systems segments. In the Industrial segment, the plan includes headcount reductions at Textron Specialized Vehicles, resulting from lower demand for certain of our powersports products which we anticipate will continue, and at Kautex, due to reduced demand for fuel systems from European automotive manufacturers. In both the Bell and Textron Systems segments, the plan includes targeted headcount reductions to improve the segments' cost structures and realign their workforces as these segments transition from legacy production contracts to more development, engineering focused contracts. Collectively, these actions are expected to result in the reduction of approximately 725 positions across the impacted segments, representing 2% of our global workforce. The restructuring plan is also expected to result in impairment charges related to both fixed and intangible assets within the powersports product line at Textron Specialized Vehicles and fixed assets at Kautex, resulting from lower planned production levels due to the impact of lower demand, which we anticipate will continue. In the fourth quarter of 2023, we expect to incur pre-tax special charges related to this restructuring plan in the range of $115 million to $135 million. We estimate severance and related costs to be in the range of $35 million to $45 million, and asset impairment charges to be in the range of $80 million to $90 million. We anticipate annualized gross cost savings of approximately $75 million upon completion of the restructuring plan. Cash outflows for this restructuring will occur primarily in 2024 and are estimated to be in the range of $35 million to $45 million. We anticipate that this plan will be substantially completed in the first half of 2024."
CRWD

Hot Stocks

16:10 EST Crowdstrike reports Q3 ARR up 35% from last year to $3.15B - Non-GAAP subscription gross margin was 80%, compared to 78% in the third quarter of fiscal 2023.
HPE

Hot Stocks

16:07 EST HP Enterprise raises quarterly dividend to 13c from 12c per share - The dividend is payable on January 11, 2024, to stockholders of record as of the close of business on December 13, 2023.
MAXN

Hot Stocks

16:07 EST Maxeon Solar begins investigation of several companies for patent infringement - Maxeon Solar Technologies announced that it has initiated an investigation of several companies for infringement of Maxeon patents pertaining to TOPCon, or Tunnel Oxide Passivated Contact, solar cell technology in the U.S. Several companies have announced plans to import into the United States or manufacture in the United States solar panels that utilize TOPCon solar cells. In response, Maxeon has begun actively monitoring the United States market for the presence of potentially infringing products. The innovations behind Maxeon IBC, Shingled Hypercell, and TOPCon technologies are protected by a patent portfolio of over 1,600 granted patents and over 360 pending patent applications in the U.S., China, Australia, Japan, Korea, Germany, France, and the Netherlands.
XCUR

Hot Stocks

16:05 EST Exicure discloses Nasdaq listing deficiency notice - Exicure "announced it received a notice of non-compliance from Nasdaq Stock Market LLC on November 22, 2023 notifying the Company that, as a result of the Company's failure to timely file its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) , which requires listed companies to timely file all periodic financial reports with the U.S. Securities and Exchange Commission."
WDAY

Hot Stocks

16:04 EST Workday reports Q3 operating cash flow $450.8M - Q3 operating cash flows were $450.8M compared to $408.7M in the prior year. Free cash flows were $390.8M compared to $349.8M in the prior year.
WDAY

Hot Stocks

16:03 EST Workday reports total subscription revenue backlog $18.45B, up 30.9% - Total subscription revenue backlog was $18.45B, up 30.9% from the same period last year. 12-month subscription revenue backlog was $6.05B, and 24-month subscription revenue backlog was $10.58B, up 21.9% and 22.7% year over year, respectively.
BDRX

Hot Stocks

16:00 EST Biodexa Pharmaceuticals PLC-ADR trading resumes
BRK.A BRK.B

Hot Stocks

15:59 EST Berkshire Hathaway says Charlie Munger has died - Berkshire Hathaway issued a news release that states: "Berkshire Hathaway a few minutes ago was advised by members of Charlie Munger's family that he peacefully died this morning at a California hospital. Warren Buffett, CEO of Berkshire Hathaway, wishes to say: 'Berkshire Hathaway could not have been built to its present status without Charlie's inspiration, wisdom and participation.' The family will handle all affairs pursuant to Charlie's instructions."
RGCO

Hot Stocks

15:49 EST RGC Resources raises annual dividend to 80c per share - The board of directors of RGC Resources, at its meeting on November 27, declared a quarterly dividend of 20c per share on the company's common stock. The indicated annual dividend is 80c per share, a 1c or 1.3% per share increase over the prior annual level. Paul Nester, CEO of RGC Resources, stated, "The Roanoke Gas utility continues to deliver solid operational and financial performance. Further, we look forward to seeing the MVP completed in 2024. This dividend increase, our 20th annual increase, reflects our commitment to deliver long-term shareholder value." The dividend will be paid on February 1, 2024 to shareholders of record on January 17, 2024.
BDRX

Hot Stocks

15:45 EST Biodexa Pharmaceuticals PLC-ADR trading halted, volatility trading pause
PHG

Hot Stocks

15:32 EST FDA warns of safety issue with Philips' DreamStation 2 CPAP machines - As part of the U.S. Food and Drug Administration's continued commitment to protect and promote the public health, the agency is alerting patients and healthcare providers of an emerging safety issue involving Philips Respironics' DreamStation 2 Continuous Positive Airway Pressure machines used for treatment of obstructive sleep apnea. The FDA issued a safety communication to inform the public of reports involving thermal issues with the machine, some of which cited patient injuries, and to provide safety recommendations for patient use, including carefully monitoring machines for signs of overheating. The agency recently received medical device reports associated with issues, such as fire, smoke, burns and other signs of overheating while using the machine. The FDA is in ongoing discussions with the company about mitigation strategies for this safety issue and will update the public accordingly. "The FDA is committed to assuring this new safety issue is resolved expeditiously. We will continue to monitor the company's handling of this, among other safety issues, to ensure they take appropriate steps to mitigate the risk to patients," said Jeff Shuren, M.D., J.D., director of the FDA's Center for Devices and Radiological Health. "We share the public's concerns regarding the new and continued safety issues of CPAP machines and certain recalled medical devices manufactured by Philips. Addressing these safety concerns remains a top priority for the FDA."
ACN

Hot Stocks

15:11 EST Accenture acquires Ocelot Consulting, terms not disclosed - Accenture has acquired Ocelot Consulting, a cloud consultancy specializing in full-stack development, data engineering, data science, and strategy and execution for cloud modernization. The addition of Ocelot Consulting expands Accenture's Amazon Web Services engineering skills in the Midwest to help clients in North America accelerate cloud transformation-including making cloud the data backbone of the enterprise and the engine for AI-driven business reinvention. Financial terms of the transaction were not disclosed. "Ocelot Consulting increases our talent base of multi-skilled engineers to help clients build a strong digital core-powered by cloud, data and AI-and to achieve new performance frontiers," said Andy Tay, global lead of Accenture Cloud First. "Cloud is the place where most technology innovation is happening, and this acquisition is all about expanding our cloud engineering skills to help clients modernize their enterprise and accelerate business growth and innovation."
LLY

Hot Stocks

15:05 EST Lilly and PRISM BioLab in drug discovery pact on a PPI interaction target - PRISM BioLab announced that it has entered into a License and Collaboration Agreement with Eli Lilly and Company. Under the agreement, PRISM and Lilly will collaborate to discover small molecule inhibitors of a PPI target selected by Lilly utilizing PRISM's proprietary PepMetics( technology. Lilly has the option to add up to two more targets to the collaboration and is responsible for the clinical development and commercialization of resulting products. PRISM will receive upfront payments and is eligible to receive up to $660M in pre-clinical, clinical and commercial development milestones payments, as well as royalties on product sales.
FQVLF

Hot Stocks

14:41 EST First Quantum reserves all local, international legal rights regarding Cobre - First Quantum Minerals notes the announcement by the Supreme Court of Justice in Panama that it has declared Law 406 unconstitutional. "Law 406 approved the concession contract for the Cobre Panama mine on October 20, 2023. The Supreme Court has published its ruling and confirms that it intends to submit its ruling for publication in the Official Gazette immediately. The company is reviewing the ruling and continues to reserve all its local and international legal rights in regards to developments in Panama. Due to the continued illegal blockades at the Punta Rincon port and roads to the site, the Cobre Panama mine has suspended commercial production and is applying a program of Preservation and Safe Maintenance to ensure the compliance and environmental integrity of the site, preservation of the assets, and safe maintenance of the plant and facilities. The security and safety of the workforce at Cobre Panama remains a priority for the company," First Quantum stated.
COIN

Hot Stocks

14:33 EST Coinbase co-founder and director Fred Ehrsam sells almost $9M in company stock - Fred Ehrsam, co-founder and beneficial owner of Coinbase, disclosed in a regulatory filing the sale of 81,530 shares of company stock at $106.94 per share on November 22, for a total transaction amount of $8,718,851.
MDT...

Hot Stocks

14:22 EST Medtronic launches Penditure Left Atrial Appendage Exclusion System in U.S. - Medtronic (MDT) yesterday announced the launch of its Penditure Left Atrial Appendage Exclusion System in the United States. The Penditure LAA Exclusion System is an innovative, implantable clip that comes pre-loaded on a single-use delivery system for use in left atrial appendage management during concomitant cardiac surgery procedures. The Penditure clip is curved to better match the atrial anatomy and was designed without fabric for atraumatic closure and reduced inflammation. The Penditure device is the only LAA clip that can be recaptured, repositioned, and redeployed after deployment during a procedure, putting greater control in the hands of surgeons. According to MedTech Dive's Susan Kelly, the device is the newest challenger to Boston Scientific's (BSX) Watchman in a broadening market that also includes Abbott's (ABT) Amplatzer Amulet treatment and AtriCure (ATRC).
AMZN

Hot Stocks

14:00 EST Amazon debuts Q, a generative A.I. 'powered assistant designed for work' - On the AWS Blog Antje Barth wrote, in part: "..., We are announcing Amazon Q, a new generative artificial intelligence- AI-powered assistant designed for work that can be tailored to your business. You can use Amazon Q to have conversations, solve problems, generate content, gain insights, and take action by connecting to your company's information repositories, code, data, and enterprise systems. Amazon Q provides immediate, relevant information and advice to employees to streamline tasks, accelerate decision-making and problem-solving, and help spark creativity and innovation at work. Amazon Q offers user-based plans, so you get features, pricing, and options tailored to how you use the product. Amazon Q can adapt its interactions to each individual user based on the existing identities, roles, and permissions of your business. AWS never uses customers' content from Amazon Q to train the underlying models. In other words, your company information remains secure and private. In this post, I'll give you a quick tour of how you can use Amazon Q for general business use. For information on how developers and IT professionals can use Amazon Q, see: Amazon Q brings generative AI-powered assistance to IT pros and developers. preview, For information on how business analysts can use Amazon Q in QuickSight, see: New Amazon Q in QuickSight uses generative AI assistance for quicker, easier data insights ..." Reference Link
BAC

Hot Stocks

13:53 EST Bank of America ordered to pay $12M for false mortgage reporting - The Consumer Financial Protection Bureau ordered Bank of America to pay a $12M penalty "for submitting false mortgage lending information to the federal government under a long-standing federal law. "For at least four years, hundreds of Bank of America loan officers failed to ask mortgage applicants certain demographic questions as required under federal law, and then falsely reported that the applicants had chosen not to respond, the agency said in a statement. Reference Link
MRK

Hot Stocks

13:18 EST Merck raises quarterly dividend to 77c from 73c per share - Merck has declared a quarterly dividend of 77c per share of the company's common stock for Q1 of 2024. Payment will be made on January 8, 2024, to shareholders of record at the close of business on December 15, 2023.
ADBE

Hot Stocks

12:49 EST U.K.'s CMA provisionally finds Adobe's Figma deal could harm innovation - The U.K.'s CMA said it has provisionally found Adobe's $20B deal to buy Figma would likely harm innovation for software used by the vast majority of UK digital designers. According to the CMA, the deal would: "eliminate competition between two main competitors in product design software; reduce innovation and the development of new competitive products; remove Figma as a threat to Adobe's flagship Photoshop and Illustrator products." The CMA added: "Today's decision is provisional, and we will now consult on our findings and listen to any further views before reaching a final decision." Reference Link
MU

Hot Stocks

12:21 EST Micron falls after increasing operating expense outlook - Shares of Micron Technology are falling after the company this morning updated its fiscal Q1 outlook. Micron raised its outlook for operating expenses to $990M from around $900M while also upping its revenue outlook. "As a result of improved supply and demand balance and improved pricing, the Company today announced that it expects revenue will approach $4.7 billion and non-GAAP gross margins will approach breakeven for the first quarter of fiscal 2024," Micron said in a statement. Shares of Micron are down 3% to $75.42 in midday trading.
AMZN NVDA

Hot Stocks

12:13 EST AWS, Nvidia announce strategic collaboration over generative AI - Amazon Web Services (AMZN) and Nvidia (NVDA) announced an expansion of their strategic collaboration to deliver the most advanced infrastructure, software, and services to power customers' generative artificial intelligence innovations. The companies said they will bring together the best of NVIDIA and AWS technologies-from NVIDIA's newest multi-node systems featuring next-generation GPUs, CPUs, and AI software, to AWS Nitro System advanced virtualization and security, Elastic Fabric Adapter interconnect, and UltraCluster scalability-that are ideal for training foundation models and building generative AI applications. "AWS and NVIDIA have collaborated for more than 13 years, beginning with the world's first GPU cloud instance. Today, we offer the widest range of NVIDIA GPU solutions for workloads including graphics, gaming, high performance computing, machine learning, and now, generative AI," said Adam Selipsky, CEO at AWS. "We continue to innovate with NVIDIA to make AWS the best place to run GPUs, combining next-gen NVIDIA Grace Hopper Superchips with AWS's EFA powerful networking, EC2 UltraClusters' hyper-scale clustering, and Nitro's advanced virtualization capabilities." "Generative AI is transforming cloud workloads and putting accelerated computing at the foundation of diverse content generation," said Jensen Huang, founder and CEO of NVIDIA. "Driven by a common mission to deliver cost-effective, state-of-the-art generative AI to every customer, NVIDIA and AWS are collaborating across the entire computing stack, spanning AI infrastructure, acceleration libraries, foundation models, to generative AI services."
DUST

Hot Stocks

12:00 EST Direxion Daily Gold Miners Bear 3X ETF falls -7.8% - Direxion Daily Gold Miners Bear 3X ETF is down -7.8%, or -92c to $10.88.
HKD

Hot Stocks

12:00 EST AMTD Digital falls -7.8% - AMTD Digital is down -7.8%, or -43c to $5.06.
LZM

Hot Stocks

12:00 EST Lifezone Metals falls -8.8% - Lifezone Metals is down -8.8%, or -77c to $7.96.
CWEN

Hot Stocks

12:00 EST Clearway Energy rises 10.5% - Clearway Energy is up 10.5%, or $2.41 to $25.28.
LC

Hot Stocks

12:00 EST LendingClub rises 10.7% - LendingClub is up 10.7%, or 59c to $6.17.
GME

Hot Stocks

12:00 EST GameStop rises 12.5% - GameStop is up 12.5%, or $1.49 to $13.40.
CHEK

Hot Stocks

11:58 EST Symetryx issues open letter to Check-Cap shareholders ahead of upcoming AGM - Symetryx, a holder of 5.6% of Check-Cap Ltd. shares, issued the following open letter to shareholders. In the letter Symetryx cites, among other items, its serious concerns and reason for voting AGAINST the proposed transaction with Keystone Dental. Symetryx discusses its concerns around the actions of the Board in its evaluation and approval of the transaction, including the "highly questionable valuation" of Keystone Dental. Further, Symetryx urges all shareholders to support and vote FOR its five "highly qualified, experienced and independent director nominees who will bring accountability back to CHEK and find a more suitable merger partner. One that will not cause the alarmingly high level of dilution to the shareholders that the Keystone transaction, if approved, would entail."
SONY

Hot Stocks

11:49 EST Sony, NCSOFT sign strategic global business partnership - Video game develooper and publisher NCSOFT announced that it has signed a strategic global business partnership with Sony Interactive Entertainment. The two companies' CEOs - Taekjin Kim of NCSOFT and Jim Ryan of SIE - have met and jointly signed the partnership. Under this partnership, NCSOFT and SIE will collaborate in various global business fields, including mobile. The two companies are evaluating a range of potential opportunities with an aim to foster strategic synergy, leveraging NCSOFT's technological prowess and SIE's global leadership in the entertainment field. "This partnership with SIE is the beginning of our efforts to build various synergies together, utilizing both companies' core competencies, technological capabilities, and expertise," said Taekjin Kim, President and CEO at NCSOFT. He added, "We will deliver a new and enjoyable experience to our audience across and beyond genres and regions."
MSS

Hot Stocks

11:37 EST Maison Solutions Inc trading resumes
CABA...

Hot Stocks

11:36 EST Cabaletta Bio, Gracell slide as FDA probes risk of CAR T cell immunotherapies - Shares of Cabaletta Bio (CABA) have plunged $7.02, or nearly 38%, to $11.69 while those of Gracell Biotechnologies (GRCL) have fallen $1.08, or 20%, to $4.32 after the FDA raised concerns about the class of drugs that both companies are developing. Earlier, the FDA announced that it has received reports of T-cell malignancies, including chimeric antigen receptor CAR-positive lymphoma, in patients who received treatment with BCMA- or CD19-directed autologous CAR T cell immunotherapies. Reports were received from clinical trials and/or postmarketing adverse event data sources. The FDA said it has determined that the risk of T-cell malignancies is applicable to all currently approved BCMA-directed and CD19-directed genetically modified autologous CAR T cell immunotherapies. T-cell malignancies have occurred in patients treated with several products in the class. Currently approved products in this class include the following: Bristol Myers' (BMY) Abecma and Breyanzi, Legend Biotech's (LEGN) Carvykti, Novartis' (NVS) Kymriah, Kite Pharma's (GILD) Tecartus and Yescarta. "Although the overall benefits of these products continue to outweigh their potential risks for their approved uses, FDA is investigating the identified risk of T cell malignancy with serious outcomes, including hospitalization and death, and is evaluating the need for regulatory action," the agency stated. Reference Link
AMZN

Hot Stocks

11:31 EST AWS announces availability of Amazon S3 Express One Zone - At AWS re:Invent, Amazon Web Services announced the general availability of Amazon Simple Storage Service Express One Zone, "a new high-performance, single-zone Amazon S3 storage class purpose-built to deliver consistent, single-digit millisecond data access for customers' most latency-sensitive applications."
AMZN

Hot Stocks

11:30 EST AWS unveils next generation AWS-designed chips - At AWS re:Invent, Amazon Web Services (AMZN) announced the next generation of two AWS-designed chip families-AWS Graviton4 and AWS Trainium2. "Graviton4 and Trainium2 mark the latest innovations in chip design from AWS. With each successive generation of chip, AWS delivers better price performance and energy efficiency, giving customers even more options-in addition to chip/instance combinations featuring the latest chips from third parties like AMD (AMD), Intel (INTC), and NVIDIA (NVDA)-to run virtually any application or workload on Amazon Elastic Compute Cloud."
CHRS SHJBF

Hot Stocks

11:21 EST Coherus, Junshi announces publication of OS results from JUPITER-02 study - Coherus BioSciences and Shanghai Junshi Biosciences announced the publication of the final overall survival results from the pivotal JUPITER-02 study, a randomized, double-blind, placebo-controlled, international, multi-center Phase 3 clinical trial evaluating the immune checkpoint inhibitor LOQTORZI, in combination with the chemotherapy agents gemcitabine and cisplatin, as a first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma in the Journal of the American Medical Association. As previously reported at the 2023 American Society of Clinical Oncologists Annual Meeting, the final analysis revealed a 37% reduction in the risk of death in NPC patients treated with toripalimab plus chemotherapy versus chemotherapy alone. In October, Coherus and Junshi announced the U.S. Food and Drug Administration approval of LOQTORZI in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced NPC, and as monotherapy for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. Coherus plans to launch LOQTORZI in the United States in January 2024. Titled Toripalimab plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma, the paper highlights the addition of LOQTORZI to gemcitabine-cisplatin chemotherapy as first-line treatment for patients with recurrent or metastatic NPC provided superior OS compared to GP alone. The median OS was not reached in the LOQTORZI arm and was 33.7 months in the placebo arm. The 2-year and 3-year OS rates were 78.0% vs. 65.1%, and 64.5% vs. 49.2% respectively. A consistent effect on OS, favoring the LOQTORZI arm, was observed in the majority of the subgroups, including PD-L1 expression and EBV copy number high and low subgroups. The addition of LOQTORZI to chemotherapy also provided superior progression-free survival compared to chemotherapy alone, with a median PFS of 21.4 vs. 8.2 months. The safety profile was consistent with that previously reported in other toripalimab clinical trials and consistent with the PD-1 inhibitor class.
NVAX...

Hot Stocks

11:16 EST Singapore says Nuvaxovid COVID vaccine won't be available under NVP as of Jan. 1 - The Singapore Ministry of Health stated in a notice posted to its website: "From 1 January 2024, the Novavax/Nuvaxovid COVID-19 vaccine will no longer be available under the National Vaccination Programme, NVP, as the existing formulation of the vaccine, which is based on the original COVID-19 strain, is no longer supplied by the manufacturer, and Singapore's existing stock will expire on 31 December 2023. Novavax is in the process of filing for regulatory approval for its updated COVID-19 XBB.1.5 vaccine formulation. Further updates will be provided when Novavax has successfully filed for regulatory approval." Reference Link
ENGN

Hot Stocks

11:07 EST iShares Industrials Sector Bond Fund trading resumes
CSCO AMZN

Hot Stocks

11:04 EST Cisco announces launch of new business metrics on AWS - At AWS re:Invent, Cisco (CSCO) announced new business metrics in Cisco Cloud Observability. "Powered by the Cisco Observability Platform to enhance business context for modern applications running on Amazon Web Services, AWS, this latest release also supports integration with AWS services and application performance monitoring correlation and provides end-to-end visibility into the performance of cloud native applications," the company stated. Reference Link
ENGN

Hot Stocks

11:02 EST iShares Industrials Sector Bond Fund trading halted, volatility trading pause
HOLO

Hot Stocks

10:32 EST MicroCloud Hologram to provide CMS for Chinese new energy vehicle company - MicroCloud Hologram announced that its subsidiary is providing CMS for China's largest new energy vehicle company. By signing the Generalized Streaming Media Control System Development Agreement, HOLO is expected to usher in a breakthrough in the new energy vehicle business. According to the agreement, HOLO provides the design and development program of a common streaming media control system. Its main contents are as follows: first, providing hardware and software design solutions for the system, which are divided into solutions for the three modules of camera, controller and display. Second, providing solutions for data analysis, optical analysis, platform-based analysis, system analysis, and imaging analysis. Third, to do the relevant EMC, performance, environment and other tests and delivery in the way satisfied by the new energy vehicle company. Fourth, verify the above solutions together with the company. Fifth, if there is a need to change the condition of the new energy vehicle models, we will cooperate with the vehicle company to complete the change. Sixth, reserve expandable artificial intelligence functions. HOLO will provide integrated holographic vision software and hardware solutions for new energy vehicles, including holographic light detection and ranging solutions based on holographic technology, holographic vision point cloud algorithm architecture design, technical hologram solutions, holographic light sensor chip design, and holographic vehicle intelligent vision technology. Providing new energy vehicle companies with holographic advanced driver assistance system software and hardware development services. Given this new energy vehicle company is China's largest company in the field of new energy vehicles, and also acclaimed for the largest sales volume of new energy vehicles in the world, the enterprise has occupied a huge market, which means the cooperation between the two listed company's will bring positive financial impact on the overall operating income of the two sides.
MSS

Hot Stocks

10:32 EST Maison Solutions Inc trading halted, volatility trading pause
LEGN...

Hot Stocks

10:20 EST FDA probing risk of T-cell malignancy following CAR T cell immunotherapies - The FDA announced that it has received reports of T-cell malignancies, including chimeric antigen receptor CAR-positive lymphoma, in patients who received treatment with BCMA- or CD19-directed autologous CAR T cell immunotherapies. Reports were received from clinical trials and/or postmarketing adverse event data sources. The FDA said it has determined that the risk of T-cell malignancies is applicable to all currently approved BCMA-directed and CD19-directed genetically modified autologous CAR T cell immunotherapies. T-cell malignancies have occurred in patients treated with several products in the class. Currently approved products in this class include the following: Bristol Myers' (BMY) Abecma and Breyanzi, Legend Biotech's (LEGN) Carvykti, Novartis' (NVS) Kymriah, Kite Pharma's (GILD) Tecartus and Yescarta. Although the overall benefits of these products continue to outweigh their potential risks for their approved uses, FDA is investigating the identified risk of T cell malignancy with serious outcomes, including hospitalization and death, and is evaluating the need for regulatory action. Reference Link
SPR

Hot Stocks

10:20 EST Spirit AeroSystems trading resumes
SHOP

Hot Stocks

10:15 EST Shopify says merchants drive record-high $9.3B in Black Friday-Cyber Monday sales - Shopify merchants reached a record of $9.3B in sales over Black Friday-Cyber Monday weekend - a 24% increase from last year, the company said. From early Friday in New Zealand to late Monday in California, more than 61M consumers globally purchased from brands powered by Shopify. Shopping peaked when collective sales reached $4.2M per minute at 12:01 p.m. EST on Black Friday. Shopify also noted that the hottest product categories were apparel and accessories, health and beauty, and home and garden; average cart price was $108.12 or $107.53 on a constant currency basis; the top selling countries were U.S., U.K., Australia, Canada, and Germany; the top selling cities were Los Angeles, New York, and London; and cross-border orders represented 15% of all global orders.Reference Link
SPR

Hot Stocks

10:07 EST Spirit AeroSystems COO, President of Commercial Sam Marnick departs - Spirit AeroSystems announced the departure of Sam Marnick, EVP and COO, President, Commercial from the Company. As part of this transition, Spirit is making organizational changes to strengthen its focus on quality and operational performance. CEO Patrick Shanahan said that Terry George will serve as interim Senior Vice President, leading site operations in Wichita, Kan., and Tulsa, Okla., including Fabrication, Operations Engineering, Tooling, and Facilities. Program leaders who previously reported to Marnick will now report directly to Shanahan.
SB

Hot Stocks

10:00 EST Safe Bulkers falls -6.6% - Safe Bulkers is down -6.6%, or -24c to $3.46.
CLCO

Hot Stocks

10:00 EST Cool Company falls -8.9% - Cool Company is down -8.9%, or -$1.20 to $12.23.
AXL

Hot Stocks

10:00 EST American Axle falls -9.0% - American Axle is down -9.0%, or -65c to $6.54.
ANVS

Hot Stocks

10:00 EST Annovis Bio rises 8.0% - Annovis Bio is up 8.0%, or 59c to $7.98.
CWEN

Hot Stocks

10:00 EST Clearway Energy rises 8.0% - Clearway Energy is up 8.0%, or $1.82 to $24.69.
STG

Hot Stocks

10:00 EST Sunlands Online rises 10.4% - Sunlands Online is up 10.4%, or 65c to $6.91.
CREV

Hot Stocks

09:56 EST Carbon Revolution PLC trading resumes
X

Hot Stocks

09:52 EST U.S. Steel higher after CNBC says 5 bids expected - Five different parties are expected to bid for US Steel and final bids are due Friday, CNBC's David Faber reports, citing sources. The shares are up 1% to $35.21 in morning trading.
CADL

Hot Stocks

09:50 EST Candel Therapeutics Inc trading resumes
LTRN

Hot Stocks

09:49 EST Lantern Pharma treatment of diffuse large B-cell lymphoma granted orphan status - Lantern Pharma's treatment of diffuse large B-cell lymphoma/high-grade B-cell lymphoma with MYC and BCL2 rearrangements was granted FDA orphan status, according to a post to the agency's website. Reference Link
GEHC

Hot Stocks

09:47 EST GE HealthCare reports FDA 510K clearance of Critical Care Suite 2.1 - GE HealthCare announced US FDA 510K clearance of Critical Care Suite 2.1 featuring a Pneumothorax algorithm for the detection, notification, triage and diagnosis of PTX. The updated PTX algorithm expands Critical Care Suite's on-device triage capabilities by providing immediate notification of the presence or absence of pneumothorax, as well as an overlay display both on-device and in PACS to assist with PTX localization, GE HealthCare said.
SUPV

Hot Stocks

09:47 EST Grupo Supervielle falls -5.2% - Grupo Supervielle is down -5.2%, or -17c to $3.10.
AXL

Hot Stocks

09:47 EST American Axle falls -7.1% - American Axle is down -7.1%, or -51c to $6.68.
CLCO

Hot Stocks

09:47 EST Cool Company falls -8.2% - Cool Company is down -8.2%, or -$1.10 to $12.32.
GB

Hot Stocks

09:47 EST Global Blue rises 4.7% - Global Blue is up 4.7%, or 21c to $4.71.
SDRL

Hot Stocks

09:47 EST Seadrill rises 5.7% - Seadrill is up 5.7%, or $2.42 to $44.98.
CWEN

Hot Stocks

09:47 EST Clearway Energy rises 7.6% - Clearway Energy is up 7.6%, or $1.74 to $24.61.
CREV

Hot Stocks

09:46 EST Carbon Revolution PLC trading halted, volatility trading pause
DRCT

Hot Stocks

09:39 EST Direct Digital Holdings Inc trading resumes
KSCP

Hot Stocks

09:37 EST Knightscope reseller TS&L expands project scope with university in Tennessee - Knightscope announced another expansion sale through Knightscope Authorized Partner Transportation Solutions & Lighting, Inc., - Safety and Security Division - National Safety Systems to supply, install, and support 14 solar powered K1 Blue Light Emergency Towers throughout a university campus in eastern Tennessee.
DRCT

Hot Stocks

09:34 EST Direct Digital Holdings Inc trading halted, volatility trading pause
BCC

Hot Stocks

09:34 EST Boise Cascade curtails lumber operations in Alabama, 80 roles impacted - Boise Cascade Company announced an indefinite curtailment of its lumber production in Chapman, AL. The curtailment will affect approximately 80 positions. The plywood operations at the Chapman location are not part of the curtailment. The Worker Adjustment and Retraining Notification Act notification was provided to impacted employees and specifies that operations will cease on January 28, 2024.
SYRA

Hot Stocks

09:30 EST Syra Health to provide mental health screening to law enforcement in NJ - Syra Health announced that it has secured a one-year agreement with the County of Camden Psychological Screening and Evaluation Services to provide mental health screening and evaluations to law enforcement personnel in Camden County, New Jersey. Through the agreement, Syra Health will provide pre-employment psychological testing for police officer recruits, intergovernmental transfers, and evaluations for current employees to determine fitness for duty. The need for these services highlights the range of psychological challenges prevalent among police officers. According to the National Alliance on Mental Illness or NAMI, compared to the general population, law enforcement report much higher rates of depression, PTSD, burnout, and other anxiety-related mental health conditions.
AMPL

Hot Stocks

09:25 EST Amplitude appoints former Tableau executive Francois Ajenstat as new CPO - As part of its mission to help companies build better digital products and experiences, Amplitude announced that former Tableau executive Francois Ajenstat has joined the company as its new chief product officer. With over 25 years of industry experience, Ajenstat will lead Amplitude's product management, design, and growth organization globally. The move comes as Amplitude continues to grow its business by enabling companies to understand how customers use their products. Amplitude's Digital Analytics Platform provides these companies with data they can trust, deeper insights into customer behaviors, and faster actions to improve the digital experience...Prior to joining Amplitude, Ajenstat led Tableau's product organization for 13 years as it grew from a small startup to a multi-billion dollar public company that was ultimately acquired by Salesforce. Before that, Ajenstat spent a decade at Microsoft driving the business and product strategy for SQL Server and Microsoft Office and helping to define the company's environmental sustainability strategy.
SPR

Hot Stocks

09:25 EST Spirit AeroSystems trading halted, news pending
LEXX

Hot Stocks

09:24 EST Lexaria announces additional results from human pilot study of DehydraTECH - Lexaria Bioscience additional interim results from a human pilot study evaluating DehydraTECH technology for the oral delivery of the glucagon-like peptide-1 (drug semaglutide available commercially in the branded product Rybelsus, further to its previously announced findings from this work. The Study was performed by a prominent university research center comparing a single 7 mg semaglutide dose of a Rybelsus tablet to a matching dose from Rybelsus that had been compound formulated in capsule form using DehydraTECH processing technology enhancements. It is accepted by the Food and Drug Administration that, "one role of GLP-1 is to prompt the body to produce more insulin, which reduces blood glucose." Because blood glucose levels are a key consideration in control of diabetes and other health conditions, the Study measured blood glucose levels at each of the 19 sample time points. The Control group evidenced reduced blood glucose levels by between 1.3% and 6.7% relative to the time zero baseline during the first 100 minutes of the Study. The DehydraTECH GLP-1 group evidenced reduced blood glucose levels by between 2.9% and 14.6% relative to baseline during those same initial 100 minutes. At all but the 20-minute and 240-minute sample time points, the DehydraTECH GLP-1 blood glucose levels were reduced more than evidenced by the Control group. Notably, even as long as 24 hours after dose administration, the blood glucose levels were reduced in the DehydraTECH GLP-1 group by 6.3% relative to baseline while the blood glucose level evidenced in the Control group was only reduced by 0.67%, evidencing nearly a ten-fold improvement with the DehydraTECH GLP-1. Of particular note, blood glucose levels spiked by 22.7% in the Control group after the subjects were permitted to eat a standardized meal at the 240-minute mark and a standardized snack at the 360-minute mark. Although the DehydraTECH GLP-1 subjects consumed choices of similar meals and snacks at the same times, their blood glucose levels rose by only 5.3%. It is not presently known whether the higher sustained levels of blood semaglutide delivery by DehydraTECH GLP-1 enabled greater efficacy in achieving sustained blood glucose reduction, thereby helping to attenuate the postprandial spikes in blood glucose experienced in the Control group, although this may be a plausible explanation for the difference. This Study is only meant to provide early-stage indicative information to Lexaria about the possibility of enhancing the pharmacokinetic and pharmacodynamic performance of orally delivered GLP-1 drugs to assist in guiding the Lexaria team in additional investigations. There was minor variability in the diets of the subjects at the 240-minute meal and 360-minute snack intervals noted above during the concentrated 10-hour post dosing monitoring period which could account for some of the differences in the test data, although meal and snack selection allowance was from a set of standardized choices. This Study is not complete and additional results will be reported, likely in late December or early January following the cross-over Study visit as described below. Given the small sample size of this Study, it was not sufficiently powered for statistical significance analysis, which will be a key part of any expanded studies with DehydraTECH GLP-1 undertaken in the future. Parallel to Lexaria's 2021 optimization program with DehydraTECH-processed cannabidiol , where the formulation utilized in the animal study DIAB-A22-1 demonstrated 364% higher PK performance than Lexaria's original DehydraTECH-CBD formulations, we expect to create several different DehydraTECH GLP-1 formulations to explore delivery and performance optimization of semaglutide. As seen with our past DehydraTECH-CBD advancements, Lexaria will endeavor to similarly improve performance of future DehydraTECH-GLP-1 formulations.
DSX

Hot Stocks

09:21 EST Diana Shipping announces time charter contract for m/v New Orleans - Diana Shipping announced that, through a separate wholly-owned subsidiary, it has entered into a time charter contract with Kawasaki Kisen Kaisha, Ltd. for one of its Capesize dry bulk vessels, the m/v New Orleans. The gross charter rate is $20,000 per day, minus a 5% commission paid to third parties, for a period until minimum August 15, 2025 up to maximum October 31, 2025. The charter is expected to commence on December 7, 2023. The "New Orleans" is a 180,960 dwt Capesize dry bulk vessel built in 2015. The employment of "New Orleans" is anticipated to generate approximately US$12.16 million of gross revenue for the minimum scheduled period of the time charter.
HUGE...

Hot Stocks

09:20 EST FSD Pharma provides update on litigation with GBB Drink Lab - FSD Pharma (HUGE) is providing this statement as an update regarding its litigation with GBB Drink Lab. The company said,"In May 2023, GBB filed a lawsuit against FSD Pharma alleging a material breach of a mutual nondisclosure agreement and trade secret misappropriation. FSD Pharma has categorically denied these allegations and field a Motion to Dismiss the lawsuit, which is currently pending. In the few months since filing its lawsuit against FSD Pharma, GBB began operating under the name Jupiter Wellness (JUPW) which acquired GBB"s purported "asset" known as its Safety Shot product, which now trades under the name Safety Shot, (SHOT). Regardless of the name it currently uses, GBB continues to try to use bully tactics in an effort to intimidate its competitors and critics through threats of litigation. Just as it has with FSD Pharma, SHOT has now issued additional press releases suggesting it intends to sue others, including its most recent public critic, Capybara Research, arising out of Capybara's most recently published research paper regarding Safety Shot. GBB's statements about its Safety Shot product, which SHOT claims will be released next month, have also been suspect. GBB has claimed that its product "accelerates the process of converting alcohol to sugar in the body" even though it is well-recognized and understood by the scientific community that at no point in the process of metabolizing alcohol is it converted into sugar. Similarly, shortly after Jupiter Wellness, Inc acquired GBB's assets, it claimed that GBB"s Safety Shot product, "lowers blood alcohol content by up to 50% in just thirty minutes," another extraordinary claim for which GBB provided no support. These suspect statements made by GBB and its affiliates should be carefully considered by anyone interested in alcohol detoxification products. In 2022, GBB drink lab tried to sell itself to FSD Pharma. During the due diligence process, FSD Pharma determined that GBB's proposed product did not meet FSD Pharma's expectations, that GBB did not provide requested information, and that GBB repeatedly tried to change the proposed structure of any deal. Furthermore, FSD Pharma had serious concerns about the patents at issue. Since then, FSD Pharma, through its team of world class scientists, doctors, and researchers, established a research program and developed its own products. After learning about FSD Pharma's efforts, GBB embarked on its campaign to file frivolous litigation and baselessly demanding tens of millions of dollars from FSD Pharma, a campaign it now apparently seeks to continue against others as well. FSD will continue to vigorously defend itself against such bully tactics. FSD Pharma continues to work on development of its alcohol detoxification products for the recreational and medical markets. FSD Pharma's team of scientific experts will adhere to the strict regulatory standards and perform the clinical studies one would expect of any respectable company like FSD Pharma."
SGPYY

Hot Stocks

09:15 EST Sage Group launches Sage Construction Management in Canada - Sage announces the launch of Sage Construction Management in Canada. Sage is expanding its construction cloud suite with the addition of cloud pre-construction and project management capabilities to its industry-leading construction portfolio.
JBT MRRLF

Hot Stocks

09:15 EST Marel rejects non-binding proposal from JBT Corporation - Marel (MRRLF) said: "The Board of Directors of Marel has carefully evaluated JBT Corporation's unsolicited non-binding initial proposal disclosed on 24 November 2023. The Board unanimously agreed that the proposal is not in the best interests of Marel's shareholders since it does not account for the intrinsic value of the business as well as the inherent risk of executing the proposed transaction. As previously communicated to the market, Marel has been clear that there are benefits of further consolidation in the sector and has been executing this strategy. In line with its fiduciary duties, the Board would evaluate any proposals that fully reflect the value of Marel." Reference Link
LGND LLY

Hot Stocks

09:14 EST Sermonix announces five abstracts at 2023 SABCS - Sermonix Pharmaceuticals announced that it had five abstracts accepted as poster presentations at the 2023 San Antonio Breast Cancer Symposium, SABCS, which will be held Dec. 5-9 at the Henry B. Gonzalez Convention Center in San Antonio. Three posters delve into clinical data tied to Sermonix's Evaluation of Lasofoxifene in ESR1 Mutations studies. One assesses baseline genomic alterations and the activity of lasofoxifene, Sermonix's investigational novel endocrine therapy, and Eli Lilly and Company's (LLY) CDK4/6 inhibitor abemaciclib during the ELAINE-2 study. A second poster addresses pharmacokinetics of lasofoxifene as a monotherapy and in combination with abemaciclib. The third poster is a trial-in-progress update on ELAINE-3, which is studying the efficacy and safety of lasofoxifene in combination with abemaciclib in treating locally advanced or ER+/HER2- mBC with an ESR1 mutation. Sermonix licensed Lasofoxifene globally from Ligand Pharmaceuticals (LGND)
SPT

Hot Stocks

09:14 EST Sprout Social receives ISO 27001, ISO 27701 certifications - Sprout Social announced that it has achieved ISO/IEC 27001:2013 and ISO/IEC 27701:2019 certifications for its information security management systems and privacy information management systems.
VRSSF

Hot Stocks

09:12 EST Verses Technologies files provisional patent application for next-gen AI - VERSES AI announces the filing of a provisional patent application representing an innovative method for "Knowledge Expansion" in next-generation artificial intelligence, AI, systems. VERSES Knowledge Expander enables intelligent systems to continuously learn and adapt in real-time by emulating the encoding processes of the human brain. The Company believes this technology could potentially replace the current state-of-the-art approach to artificial intelligence. "We believe that knowledge expansion is the key to enabling dynamic models, allowing agents to adapt to a changing world. It is the essence of artificial general intelligence," said Gabriel Rene, founder and CEO of VERSES.
TBLA

Hot Stocks

09:11 EST Taboola announces new, five-year deal with NBCUniversal - Taboola announced a new five-year deal with NBCUniversal News Group. Under the new agreement, NBCU News Group will continue to utilize Taboola's suite of products across its digital properties including NBC News, CNBC, MSNBC and TODAY to grow its audience, optimize user engagement, and drive revenue. "NBCUniversal News Group is one of the most iconic, trusted names in media, delivering world-class journalism, including financial and business news, entertainment, politics and more. Supporting its continued growth is a testament to the mutual trust and benefits we've developed since 2014," said Adam Singolda, CEO and Founder at Taboola. "We look forward to continuing to partner and drive growth as we're looking to create engaging experiences for consumers."
NAOV

Hot Stocks

09:10 EST NanoVibronix announces pact for clinical study of UroShield at UMich - NanoVibronix announced it has signed a Research Agreement with the Regents of the University of Michigan for a Randomized Control Trial RCT study of UroShield. Brian Murphy, Chief Executive Officer of NanoVibronix, Inc., said, "We are partnering with a team of distinguished researchers at the University of Michigan to further advance clinical evidence of the efficacy of UroShield. UroShield is cleared under the U.S. Food and Drug Administration's FDA Enforcement Discretion, and we hope positive outcomes from this independent study will support an application to the FDA for permanent clearance. RCTs are considered the 'gold standard' in clinical research, and we are pleased to be working with the team at the University of Michigan."
CTRM

Hot Stocks

09:10 EST Castor announces sale of M/V Magic Moon, completes sale of M/V Magic Phoenix - Castor Maritime announces that on November 10, 2023, the Company entered into an agreement with an unaffiliated third party for the sale of the M/V Magic Moon, a 2005-built Panamax bulk carrier vessel, for a price of $11.8 million. The vessel is expected to be delivered to its new owner by the end of the fourth quarter of 2023. The Company expects to record during the fourth quarter of 2023 a net gain of approximately $3.0 million from the sale of the M/V Magic Moon, excluding any transaction related costs. Furthermore, on November 27, 2023, the Company completed the previously announced sale of the M/V Magic Phoenix, a 2008-built Panamax bulk carrier vessel, for a price of $14.0 million, by delivering the vessel to its new owner. The Company expects to record during the fourth quarter of 2023 a net loss of approximately $2.6 million from the sale of the M/V Magic Phoenix, excluding any transaction-related costs.
INTA MSFT

Hot Stocks

09:09 EST Intapp solutions now available in Microsoft Azure Marketplace - Intapp (INTA) announced the availability of its solutions in the Microsoft (MSFT) Azure Marketplace, an online store providing applications and services for use on Azure. Intapp clients can now take advantage of the productive and trusted Azure cloud platform, with streamlined deployment and management. "Launching our solutions on the Azure Marketplace is a significant milestone and represents a further expansion of our relationship with Microsoft," said Thad Jampol, Co-Founder and Chief Product Officer at Intapp. "This milestone adds significant value for our clients by simplifying purchasing and billing and enabling innovation using both Intapp's and Microsoft's solutions - all deployed on the Azure cloud."
PHG

Hot Stocks

09:08 EST Philips launches ultra lightweight, flexible MR Smart Fit coils - Royal Philips launched three new fit for purpose MR Smart Fit coils at #RSNA23. RF coils are an essential part of every MRI scan. The new ultra-light weight coils provide exceptional flexibility, significant reduction in patient setup time and optimization with Philips' SmartSpeed AI solution, which allows for better image quality resolution and improved diagnostic confidence for healthcare providers. "Our new Smart Fit coils are an integral part of our patient-centric workflows in MR, with a focus on raising productivity and simplifying workflow," said Ruud Zwerink, General Manager Magnetic Resonance at Philips. "They combine with our advanced AI-powered software that reduces scanning time and dramatically cuts the number of steps needed to complete an exam. These newly designed coils will help to speed up MR exam process, improving both efficiency and the overall experience for patients."
OKTA

Hot Stocks

09:07 EST Okta names Jon Addison CRO and Kerry Ok CMO - Okta announced two new executive appointments. Jon Addison has been named Okta's Chief Revenue Officer CRO and Kerry Ok has been named Okta's Chief Marketing Officer CMO . Jon will report to Okta's CEO and co-founder, Todd McKinnon, and Kerry will report to Okta's Chief Customer Officer, Eric Kelleher. Jon was named Interim CRO in February 2023, while continuing to serve as General Manager of EMEA, a role he held since joining Okta two years ago. As CRO, he will lead the team responsible for helping customers solve their identity challenges using Okta's Workforce and Customer Identity Clouds. He has helped build a team that is expert at understanding customers' business needs and identifying solutions that will protect them for a future where identity is a growing priority.
SCLX

Hot Stocks

09:07 EST Scilex announces pharmacy initiative to stock ELYXYB in over 500 stores - Scilex announced that it has entered into an agreement with a leading pharmacy chain in the U.S. to stock ELYXYB in over 500 stores which do not currently stock ELYXYB. Scilex is also in the process of negotiating similar potential stocking arrangements with other major pharmacy chains in the U.S.
ADSK

Hot Stocks

09:07 EST Autodesk appoints Joe Speicher as its first Chief Sustainability Officer - Autodesk appointed Joe Speicher as the company's first Chief Sustainability Officer, which took effect in July. During his tenure at Autodesk, Speicher has held various leadership roles across the sustainability and Foundation organization. In his new role, Speicher reports to Autodesk's CFO. Speicher continues to lead the Autodesk Foundation, a philanthropic organization dedicated to supporting innovative solutions to the world's most pressing social and environmental challenges. He also chairs Autodesk's ESG Steering Committee.
AMZN

Hot Stocks

09:07 EST Amazon announces record-breaking Black Friday, Cyber Monday holiday event - Amazon announced that its extended Black Friday and Cyber Monday holiday shopping event, which kicked off November 17 and continued through November 27, was its biggest ever compared to the same 11-day period ending on Cyber Monday in previous years. Customers around the world purchased more than one billion items on Amazon, with shoppers saving nearly 70% more on Amazon during the 11 days of deals compared to the same period last year. Amazon also announced it will be dropping new deals every day through December 24.
GOVX

Hot Stocks

09:06 EST GeoVax Labs announces COVID-19 vaccine data to be presented at WVC - GeoVax Labs announced the presentation of data from the active development program for its next-generation COVID-19 vaccine, GEO-CM04S1, including Phase 2 clinical trial data. The data include some of which was recently published in the journal Vaccines and can be accessed here: GEO-CM04S1 Publication. The data were presented during the World Vaccine Congress, WVC, West Coast conference, being held in Santa Clara, CA from November 27-30, 2023. The presentation, titled "COVID-19 Vaccines for Immunocompromised Patients," was delivered by Don Diamond, PhD, Professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center. David Dodd, GeoVax Chairman and CEO, commented, "Safeguarding individuals at the highest risk in our society requires the development of next-generation COVID-19 vaccines. Ideally, these vaccines should induce enhanced immune responses after the first dose, provide long-lasting protection, and effectively address the ongoing emergence of new variants. Current mRNA vaccines and monoclonal antibody therapies often fall short in quickly delivering sufficient protective immunity to immunocompromised patients. Given the persistent evolution of variants, the public health community faces a continuous challenge to mitigate the impact of infections, ultimately minimizing the risks of severe illness, hospitalizations, and mortality. Vaccines like GEO-CM04S1, designed to be "variant-agnostic," are becoming increasingly vital in addressing these risks, protecting the most vulnerable populations, and bolstering our ability to combat infectious threats effectively."
ARBE

Hot Stocks

09:05 EST Arbe Robotics releases the production version of its Radar Processor - Arbe Robotics announced that it has released the production version of its Radar Processor, which is used for OEM development projects and B-Sample radars with the production functionality of Arbe Tier-1s. Arbe's Radar Processor complements the company's production chipset portfolio which already includes production RF chips. "Our powerful Perception Radar solution requires the strongest processing chip on the market today, which we designed at Arbe," says Kobi Marenko, Chief Executive Officer at Arbe. "Our patented processor has the richest point cloud output that supports the OEMs perception needs while maintaining low power consumption, a feat no other company was able to achieve. Arbe's sophisticated perception radar remains the only solution that can support the needs of hands-free driving at an affordable price, providing unmatched safety that can scale the industry to autonomy."
CADL

Hot Stocks

09:05 EST Candel Therapeutics reduces workforce by 50%, prioritizes CAN-3110 development - Candel Therapeutics announced a strategic restructuring to focus on continuation and expansion of development of CAN-3110 as well as the enLIGHTEN Discovery Platform, while reducing the Company's workforce and expenses associated with enabling commercial readiness of CAN-2409. The Company expects to present initial activity and biomarker data for repeated injections of CAN-3110 in recurrent high-grade glioma in the second half of 2024 and new data for the second drug candidate based on the enLIGHTEN Discovery Platform in Q3 2024. The Company plans to continue to collect clinical data for key readouts for CAN-2409 in non-small cell lung cancer, with topline overall survival data of the open label phase 2 clinical trial expected in Q2 2024; pancreatic cancer, with an update on overall survival based on an interim analysis of the randomized, open label clinical trial in Q2 2024; and prostate cancer, with topline data for both fully enrolled randomized, blinded, placebo-controlled phase 2 and phase 3 clinical trials in Q4 2024. Based on the encouraging clinical activity data for CAN-2409, the large number of patients that might benefit from this treatment, and the investments needed for commercialization, the Company plans to explore the right partnering opportunities for the future development of this asset. To focus on delivering on the value-creating catalysts in 2024, on November 28, 2023, Candel implemented a reduction in its workforce of approximately 50%. The Company estimates that it will incur a one-time restructuring charge of approximately $0.7 million in the fourth quarter of 2023 related to severance and healthcare and related benefits for terminated employees. Candel expects that the reduction in workforce, coupled with the reduced operating costs, will enable the Company's existing cash resources to fund its revised operating plan into the fourth quarter of 2024, enabling the achievement of key catalysts next year.
ANIK

Hot Stocks

09:04 EST Anika announces first surgeries performed using Integrity Implant System - Anika Therapeutics announced that the first surgeries using the Integrity Implant System were successfully performed by Dr. Christopher Baker at the Florida Orthopaedic Institute in Tampa, FL. Integrity, comprised of a hyaluronic acid-based scaffold with bone and tendon fixation components and single use arthroscopic delivery instruments, is designed to protect an injured tendon and promote healing in rotator cuff repair and other tendon procedures. The system was fully cleared by the FDA in August of 2023. This marks the beginning of the limited U.S. market release ahead of schedule that will ramp to a full market release during the first quarter of 2024. "The successful first surgeries using Anika's new Integrity Implant System mark another key milestone in the build out of our regenerative product portfolio as we continue to provide differentiated solutions to surgeons for rotator cuff procedures," said Cheryl Blanchard, Ph.D., Anika's President and CEO. "The HA-based scaffold, together with the instrumentation and fixation components, provide a seamless, efficient, and elegant rotator cuff repair solution. While having a strong implant at time zero is critically important in rotator cuff repairs, the instrumentation and delivery are just as important, and we believe we have nailed it. The feedback received after the procedure exceeded our expectations highlighting the system's ease of use and strength of the HA-based scaffold. We believe that Integrity is truly a game changer for surgeons and their patients and look forward to extending this exciting technology to other tendon repairs, for example, in the foot and ankle."
INVO

Hot Stocks

09:04 EST INVO Bioscience regains Nasdaq compliance - INVO Bioscience announced the company received notice from The Nasdaq Capital Market, dated November 22, informing INVO that it has regained compliance with the minimum stockholders' equity requirement as set forth under NASDAQ Listing Rule 5550(b)(1) for continued listing on Nasdaq. The company will be subject to a mandatory panel monitor for a period of one year from the date of the notification.
PEN

Hot Stocks

09:04 EST Penumbra enrolls first patient in trial of Lightning Flash thrombectomy system - Penumbra has enrolled the first patient in STORM-PE, a randomized controlled trial evaluating anticoagulation alone vs anticoagulation plus Lightning Flash for the treatment of pulmonary embolism - PE -. In partnership with PERT Consortium, a multi-disciplinary group dedicated to improving the care of patients with PE, the STORM-PE trial aims to advance the understanding of the role of computer assisted vacuum thrombectomy - CAVT - in the management of acute PE, with a goal of improving the outcomes for patients with this life-threatening condition. STORM-PE will enroll up to 100 participants at up to 20 sites. Penumbra's Lightning Flash can be used to remove emboli and thrombi from vessels of the peripheral arterial and venous systems and can be used for the treatment of PE.
ATNF

Hot Stocks

09:03 EST 180 Life Sciences announces review of strategic alternatives - 180 Life Sciences announced that its Board of Directors has initiated a process to evaluate potential strategic alternatives with the intent to unlock and maximize shareholder value. In consultation with financial and legal advisors, the Company intends to consider a broad range of strategic, operational and financial alternatives, and is exploring a full range of options. There is no assurance that the strategic review process will result in the approval or completion of any specific transaction or outcome. 180 Life Sciences has not established a timeline for completion of the review process and does not intend to comment further unless and until its Board of Directors has approved a definitive course of action, or it is determined that other disclosure is necessary or appropriate.
CART

Hot Stocks

09:01 EST Instacart, JD Sports announce new partnership - JD Sports and Instacart announced a new partnership to launch same-day delivery from more than 500 JD Sports and Finish Line stores nationwide via the Instacart App and website. JD Sports is one of the first sports-fashion retail partners to leverage Instacart's technologies, giving customers access to same-day delivery for more than 16,000 products, including popular athletic footwear and apparel brands like Nike, Jordan, adidas, Puma and more, delivered in as fast an hour.
WKEY LAES

Hot Stocks

08:58 EST SEALSQ to increase investments in AI-enhanced semiconductors, IoT innovations - WISeKey International Holding (WKEY), in conjunction with its subsidiary SEALSQ Corp (LAES), announced its intention to increase its investments in Artificial Intelligence (AI). Integration of AI with Cybersecurity and IoT will propel the creation of advanced predictive analysis systems and enhance the operational efficiency and security of IoT devices. SEALSQ's AI strategy would include further investments in new post-quantum chips, which are currently under development and expected to be commercialized in 2025. These chips are designed to improve AI performance in semiconductors, bringing unprecedented capabilities to the technology world. SEALSQ's wide range of solutions, including secure elements, root of trust, cryptographic keys, and hardware security modules, underscore its commitment to spearheading technological advancements while fortifying semiconductors against potential vulnerabilities.
CADL

Hot Stocks

08:58 EST Candel Therapeutics Inc trading halted, news pending
SPRC

Hot Stocks

08:57 EST SciSparc adopts limited duration shareholder rights plan - SciSparc announced that its Board of Directors has unanimously adopted a limited duration shareholder rights plan, effective immediately. The Board did not adopt the Rights Plan in response to a specific takeover threat. The Rights Plan is not intended to prevent or interfere with any action with respect to SciSparc that the Board determines to be in the best interests of the Company and its shareholders. Instead, it will position the Board to fulfill its fiduciary duties on behalf of all shareholders by ensuring that the Board has sufficient time to make informed judgments about any attempts to control or significantly influence SciSparc. The Rights Plan will encourage anyone seeking to gain a significant interest in SciSparc to negotiate directly with the Board prior to attempting to control or significantly influence the Company. The Rights Plan is similar to those adopted by other publicly traded companies, and does not contain any dead-hand, slow-hand, no-hand or similar feature that limits the ability of a future Board to redeem the rights. Pursuant to the Rights Plan, SciSparc will issue one special purchase right for each ordinary share outstanding as of the close of business on December 8, 2023. While the Rights Plan is effective immediately, the rights generally would become exercisable only if an entity, person or group acquires beneficial ownership of 10% or more of SciSparc's outstanding ordinary shares in a transaction not approved by the Company's Board. In that situation, each holder of a right will have the right to purchase one ordinary share at a purchase price of $0.001 per share. In addition, at any time after an entity, person or group acquires 10% or more of the Company's ordinary shares, the Company's Board of Directors may exchange one ordinary share of the Company for each outstanding right. The Rights Plan has a 364-day term, expiring on November 27, 2024.
STER

Hot Stocks

08:56 EST Sterling Check launches enhanced capabilities in Asia Pacific region - Sterling Check announced that Sterling RISQ is being rebranded as 'Sterling' in the Asia Pacific region, aligned with technology enhancements to deliver best-in-class global background screening and identity programs along with unrivalled local expertise. Sterling's brand transition in this region, and the strengthening of global screening capabilities, comes as employers around the world are increasingly hiring internationally in the search for the best talent. Sterling's local presence and expertise, with employees based in Australia, Singapore, Malaysia, Hong Kong, India, the Philippines, and mainland China, combined with the company's extensive global reach and innovative technology enhancements enables Asia Pacific employers to benefit from fast, effective screening programs that are scalable while delivering globally consistent candidate experiences.
PODC

Hot Stocks

08:51 EST PodcastOne announces integration of SourceAudio's music licensing service - PodcastOne announced the integration of SourceAudio's music licensing service, PodcastMusic.com. This partnership revolutionizes podcasting, offering personalized and efficient tools for podcasters to discover and select sound designs aligned with their shows. "This partnership marks a significant leap forward in our commitment to delivering an unparalleled podcasting experience," said Kit Gray, President and Co-Founder of PodcastOne. "By leveraging SourceAudio's AI technology, we are empowering our podcasters to discover audio elements that resonate with the essence of their shows, creating a more engaging and immersive listening experience."
RCAT

Hot Stocks

08:49 EST Red Cat announces management changes - Red Cat announces several management changes. George Matus, founder and CEO of wholly owned subsidiary, Teal Drones, has been appointed as Chief Technology Officer of Red Cat. Concurrently, Allan Evans, Chief Operating Officer, is departing to become CEO of Unusual Machines, which is presently seeking to acquire the Company's Consumer segment consisting of Rotor Riot and Fat Shark Holdings. Following the sale of the Consumer segment, the Company is expected to be the largest shareholder in Unusual Machines. Finally, Joseph Hernon plans to retire at the end of his employment contract on June 30, 2024 as he reaches normal retirement age.
AIMD

Hot Stocks

08:48 EST Ainos announces manufacturing of VELDONA GMP clinical batch - Ainos announced that its contract manufacturer, Swiss Pharmaceutical, has completed manufacturing of a Good Manufacturing Practice Clinical Batch of the Company's VELDONA investigational new drugs. Swiss Pharma has conducted testing, manufacturing, and packaging of VELDONA's GMP Clinical Batch for Ainos under both Pharmaceutical Inspection Co-operation Scheme Good Manufacturing Practice and the United States Food and Drug Administration's Current Good Manufacturing Practice regulations. Following release of the GMP Clinical Batch by Swiss Pharma, Ainos intends to initiate the preparation of Chemistry, Manufacturing, and Controls information for submission of Investigational New Drug applications for several programs. The Company will initially submit an IND application for conducting Phase II studies for treatment of mild COVID-19 symptoms during the first quarter of 2024. After this, Ainos intends to submit a number of additional IND applications during the first half of 2024, including Phase III studies for treatment of oral warts in HIV-seropositive patients, Phase III studies for Sjogren's syndrome, and Phase III studies for the common cold. Following promising results from preclinical studies of VELDONA against COVID-19, Ainos is ready to initiate "A Multicenter, Randomized, Parallel, Phase II Study to Evaluate the Efficacy of VELDONA in Patients with Mild COVID-19" in Taiwan. This study aims to evaluate the efficacy of VELDONA in subjects presenting mild symptoms of COVID-19. Subjects will receive either a daily oral dose of VELDONA or a standard of care for a duration of five days, and will be evaluated throughout a 28-day study period.
STXS

Hot Stocks

08:48 EST Stereotaxis announces first patients treated using Genesis RMN System - Stereotaxis announced that physicians have built upon their two-decades of leadership in robotic heart care with the successful treatment of first patients using the newest advancement in the technology, the Genesis Robotic Magnetic Navigation, RMN, System. Electrophysiologists at Baptist Health Lexington were the first globally to pioneer clinical use of Robotic Magnetic Navigation for the treatment of patients in 2003. The robotic technology represented an entirely novel way to address heart rhythm disorders in a minimally invasive procedure with the benefits of robotic precision and safety. In the ensuing years, the electrophysiology department, under the leadership of Dr. Gery Tomassoni, played central roles in advancing the technology and clinical science: authoring multiple scientific publications, participating in national clinical studies, guiding technology developments, and using robotic technology to treat over 1000 cardiac patients, including those with the most complex conditions. "Our long-term collaboration with Baptist Health Lexington has been instrumental for technological progress, scientific discovery, and clinical care," said David Fischel, Chairman and CEO of Stereotaxis. "We look forward to expanding the success of robotic ablation practices for patients suffering from arrhythmias in Kentucky."
UPXI...

Hot Stocks

08:46 EST Upexi's Tytan Tiles launches on Walmart.com - Upexi (UPXI) announced the Company's children's toy brand, Tytan Tiles, posts record sales on Amazon (AMZN), becoming the #1 New Release for Preschool Building sets. Tytan Tiles has also launched its licensed Disney Frozen product on Walmart.com (WMT), under the agreement previously announced with The Walt Disney Company (DIS). In one month, since Tytan Tiles launched its Disney Frozen Kit on Amazon on October 17th, 2023, it rose to #1 for Amazon's New Releases in Preschool Building Sets, #3 top seller in Magnetic Building Sets, and broke into the top 400 in all Toys and Games on Amazon. The exclusive Disney Frozen set also launched on Walmart.com on November 27th in a Cyber Monday deal.
NEWT

Hot Stocks

08:45 EST NewtekOne's Newtek Bank hires Merritt as COO of digital banking operations - NewtekOne announced that its bank subsidiary, Newtek Bank, N.A., has hired Jennifer Merritt as Chief Operating Officer, COO, of digital banking operations, effective November 27, 2023. Merritt comes to Newtek Bank with over a decade of banking experience with specific focuses on digital banking and banking-product development. Most recently, Jennifer was Senior Vice President, Strategic Operations Lead at Live Oak Bank.
MGRM

Hot Stocks

08:44 EST Monogram Orthopaedics delivers first surgical robot - Monogram Orthopaedics has delivered its first surgical robot to one of the world's largest global robotics distributors. Monogram aims to improve the standard of care in orthopedic joint replacement surgery with advanced, next-generation active surgical robotics. Approximately 88% of knee replacement surgeries are still manual. The mBos robot aims to combine safety, ease of use, streamlined cost, novel implant design, broad clinical functionality, and speed to help drive the next wave of robotic adoption in orthopedics.
DGX

Hot Stocks

08:44 EST Quest Diagnostics and Scipher Medicine collaborate in rheumatoid arhritis - Quest Diagnostics and Scipher Medicine, a precision immunology company, announced a multi-pronged collaboration designed to expand patient access to diagnostic services advancing precision medicine for rheumatoid arthritis, or RA. Under a multi-year collaboration, Quest will provide advanced RNA extraction and next-generation sequencing services for Scipher's PrismRA test. The collaboration centers on Quest's next-generation sequencing capabilities at its advanced laboratory in Marlborough, Massachusetts. Quest will extract and sequence RNA from PrismRA blood specimens to identify approximately two dozen molecular traits associated with response to TNFi therapies. Through their electronic health record, physicians receive a personalized report with a score indicating predicted response based on analysis of the complete set of laboratory and patient data.
APDN

Hot Stocks

08:43 EST Applied DNA Sciences receives Linea DNA follow-on order - Applied DNA Sciences announced the receipt of a follow-on order for Linea DNA valued above the mid-six figures. The order was placed under a long-standing supply agreement for the bulk manufacture of Linea DNA for a global manufacturer of in vitro diagnostics. Under the terms of the repeat order, deliveries are expected to commence during the fiscal quarter ending March 31, 2024, through the fiscal quarter ending December 31, 2024.
HNRA

Hot Stocks

08:43 EST HNR Acquisition provides business update on acquired entity - HNR Acquisition is an independent oil and natural gas company focused on the acquisition, development, exploration and production of oil and gas properties in the Permian Basin. The Company's assets include its interest in the Grayburg-Jackson oil field in the prolific Permian Basin in New Mexico. HNRA acquired the property by purchasing all equity interests in Pogo Resources, LLC and its subsidiary, LH Operating in the business combination that occurred on November 15, 2023. HNRA filed its Super 8-K with the SEC on November 21, 2023. LHO was a privately owned company that operated the Grayburg-Jackson field from early 2020 after acquiring the property in late 2019. The 2020 baseline production level was approximately 500 barrels of oil equivalent per day. LHO's production has increased from the baseline 500 BOE to an average of 1,388 BOE per day for the nine months ended September 30, 2023. All field production of the Company is being sold under long-term contracts to various customers in the USA. LHO had $20.3 million of revenues generating positive cash flow and $3.9 million of net income for the nine months ended September 30, 2023. As of September 30, 2023, total assets of LHO were $70.4 million. With the acquisition now completed, HNRA will report its first consolidated financials for the fiscal year ended December 31, 2023. The results from the acquisition will only be included for six weeks of the fourth quarter in the fiscal year ended December 31, 2023. Following the acquisition, all of the experienced field personnel of LHO who achieved these results have remained with the Company. The field is located in Eddy County, New Mexico in the Delaware basin of the prolific Permian Basin. LHO's holdings comprise of 13,700 contiguous leasehold acres, 343 producing wells and 207 injection wells for a total of 550 wells. The Grayburg-Jackson oil field has several large reservoir structures that range from as shallow as 1,500 feet deep to 4,000 feet deep. The field has attainable proven reserves of approximately 20 million barrels of crude oil and 6 billion cubic feet of natural gas. Since the 500 BOE per day baseline production in 2020, by the implementation of Zone 7R waterflooding, the production has increased to today's range of 1,250-1,450 BOE per day. We plan on doing the same successful workovers which will expand the existing waterflood patterns field-wide which are expected to triple field production to 4,000 BOE per day by 2027. This production increase, forecasted by our 3rd party engineer, Cobb and Associates, will increase HNRA's enterprise value to approximately $433 million on a PV-10 basis. This is our key focus in creating increasing shareholder value quarter over quarter for the balance of this decade. The existing and future production is principally comprised of waterflooded, long-lasting, low decline oil production. This creates a long-term steady revenue stream, which is a strong base to generate sustain cash flow and earnings. Additionally, because the field has over 500 wells, the geological and mechanical risks are significantly mitigated. This steady revenue stream and low-risk oil recovery waterflooding method increases the economic value of this asset. According to the United States Geological Survey, the Permian Basin is considered the largest oil and natural gas rich property in the USA. The basin is known for an extensive production history, long-life reserves and historically high drilling success rates. In 2018, the USGA did an assessment where the Delaware Basin portion of Texas and New Mexico's Permian Basin province contains an estimated 46 billion barrels of oil and 281 trillion cubic feet of natural gas.
PCVX MRK

Hot Stocks

08:41 EST Vaxcyte appoints Lee to board of directors - Vaxcyte (PCVX) announced the appointment of Jacks Lee to its Board of Directors. Most recently, Lee was Senior Vice President of Global Manufacturing and Supply at Merck (MRK)
SYF

Hot Stocks

08:41 EST Synchrony to sell Pets Best Insurance Services to Poodle Holdings - In a regulatory filing last night, Synchrony Financial disclosed that on November 23, the company entered into an agreement for the sale of its wholly-owned subsidiary, Pets Best Insurance Services, to Poodle Holdings, Inc. for consideration comprising a combination of cash and an equity interest in Independence Pet Holdings, Inc., an affiliate of the buyer. Subject to regulatory approval and other customary closing conditions, the transaction is expected to close in the first quarter of 2024, which is estimated to result in the recognition of a gain on sale, net of tax, of approximately $750M. The gain amount to be recognized is subject to change based upon the carrying amount of net assets of Pets Best and the final valuation of consideration to be received at closing, Synchrony stated.
AENT

Hot Stocks

08:40 EST Alliance Entertainment announces launch of new publishing venture - DirectToU LLC, a division of Alliance Entertainment Holding Corporation, announced that it has launched a new publishing venture under the banner of Alliance Entertainment Publications. "Alliance Entertainment acquired Collectors' Choice Music and Critics' Choice Video in 2010 and Movies Unlimited in 2015, as a way to grow our existing customer base and to tap into new avenues of sales," said Jeff Walker, CEO and CFO of Alliance Entertainment. "At the same time, we acquired a team of dedicated and talented long-time employees, many of whom worked on these brands since the beginning. These new Collectible Magazines will be written and designed by these same long-time employees, utilizing their decades of institutional knowledge of Movies, TV and Music."
ENSC

Hot Stocks

08:40 EST Ensysce Biosciences, OncoZenge sign LOI for codevelopment of BupiZenge - Ensysce Biosciences and OncoZenge signed a letter of intent to explore a strategic collaboration to accelerate the commercialization of BupiZenge in the United States. BupiZenge is OncoZenge's novel approach to treating pain caused by oral mucositis, an often severely debilitating condition of painful swelling and ulcerations of the mouth that commonly results from head and neck radiation and/or chemotherapy used to treat cancer. Left untreated, oral intake of food or fluids may be severely impeded and may adversely impact a patient's prognosis and quality of life. BupiZenge is a non-opioid oral formulation of the well-established local anesthetic bupivacaine. OncoZenge has successfully progressed BupiZenge through Phase 2 in the European Union and is currently in planning for the registrational Phase 3 program. Results from the Phase 2 study conducted in head and neck cancer patients with oral mucositis demonstrated strong efficacy in relieving pain with good safety and tolerability. The proposed collaboration aims to leverage the expertise and resources of both companies to accelerate the path to market in the United States for this innovative therapy that addresses critical unmet needs in the fields of analgesia and oncology.
SPTN

Hot Stocks

08:38 EST SpartanNash promotes Amy McClellan to Chief Customer Officer - SpartanNash promoted Amy McClellan from Senior VP, Chief Marketing Officer to Executive VP, Chief Customer Officer. McClellan was previously Senior CVP, Retail of Martin's Super Markets, where she was a customer of SpartanNash until the company acquired the grocery chain in 2019. McClellan serves on the SpartanNash Foundation Board of Trustees and the Ohio-based Buehler's Fresh Foods Board of Directors. McClellan's promotion will follow the upcoming Dec. 31 departure of SpartanNash Executive VP and Chief Customer Officer David Sisk as he leaves to devote time to other passion areas after serving for almost four years at SpartanNash. SpartanNash also has a search underway for McClellan's successor as Chief Marketing Officer.
APYX PDSB

Hot Stocks

08:38 EST Apyx Medical appoints Matthew Hill as CFO - Apyx Medical (APYX) announced the appointment of Matthew Hill to the position of CFO, effective December 4. Hill succeeds Tara Semb, whose departure was announced by the company on November 9. Hill joins Apyx Medical from PDS Biotechnology Corporation (PDSB).
DRTS

Hot Stocks

08:38 EST Alpha Tau reports interim results from trial of Alpha DaRT treatment - Alpha Tau Medical announced the release of interim results from treatment of the first five patients in the Company's safety and feasibility trial examining the use of Alpha DaRT to treat advanced pancreatic cancer, currently underway at two university hospitals in Montreal, Canada. The first five patients were treated at the Jewish General Hospital, an affiliated teaching hospital of McGill University, Faculty of Medicine in Montreal, Canada, in accordance with the study protocol calling for a pace of approximately one patient per month, pending results from the interim safety read-out from the first five patients. Levels of radium-224 activity were increased from one patient to the next. Tumor stages of the treated patients ranged from stage II to stage IV, and treated tumors were located in the pancreatic head or neck. Four of the five patients had been previously treated with chemotherapy before enrolling in the study. With respect to primary outcome measures, the Alpha DaRT procedure was deemed technically successful in all five cases, with Alpha DaRT sources successfully inserted into the target tumor. In addition, there were no reported serious adverse events deemed related to the product. The only reported adverse events deemed possibly related to the product were of severity grade 1. The first two patients, who had received the fewest number of Alpha DaRT sources, both died approximately three months after treatment, and the deaths were not related to Alpha DaRT treatment. The other three patients, who are still undergoing regular follow-up multiple months after treatment, all demonstrated stable disease responses at four weeks after treatment, i.e., neither material shrinkage nor material increase in the longest dimension of the treated tumor. The third patient treated, for whom the coverage of gross tumor volume at 16 Gy alpha radiation dose was estimated at 44% after treatment, was upgraded to partial response upon evaluation at 69 days after treatment, i.e., the treated tumor shrank by at least 30% on its longest dimension vs. the baseline measurement. The trial seeks to recruit 37 participants who have Stage II to IV pancreatic adenocarcinoma which is deemed inoperable due to non-resectability, metastasis, or lack of fitness for surgery. The study primarily examines the safety and feasibility of placing the Alpha DaRT sources in the tumor utilizing endoscopic ultrasound, and the overall safety of the procedure by measuring adverse events. In addition, the study examines the efficacy of Alpha DaRT in terms of metrics such as overall response rate, overall survival and change in blood levels of CA19-9.
REBN

Hot Stocks

08:36 EST Reborn Coffee, KIB Plug Energy Korea sign MOU for $5M investment - Reborn Coffee announced the signing of a Memorandum of Understanding, MOU, for a strategic investment of $5 million from KIB Plug Energy Korea. This investment is set to transform the coffee service model by combining premium coffee services with electric vehicle charging stations. This initiative marks a significant advancement in combining sustainable practices with everyday consumer needs. Through this collaboration, Reborn Coffee and KIB Plug Energy Korea are developing a unique way to service coffee that caters not only to the discerning tastes of coffee enthusiasts but also serves the rapidly growing community of EV users. "The MOU with KIB Plug Energy Korea showcases our deep commitment to innovation and sustainability," said Jay Kim, CEO of Reborn Coffee. "This investment marks a significant phase in our growth strategy, allowing Reborn Coffee to enhance its current offerings and pave the way for future development. Integrating EV charging stations into our coffee services is a thoughtful approach that broadens our service portfolio and responds to the rising demand for sustainable and convenient options among environmentally aware consumers."
MAMA

Hot Stocks

08:36 EST Mama's Creations launches direct-to-consumer e-commerce platform - Mama's Creations announced the launch of its nationwide direct-to-consumer e-commerce platform, offering popular MamaMancini's retail products for delivery throughout the continental United States. Adam Michaels, Chairman and CEO of Mama's Creations, commented: "Our move into e-commerce was the result of thoughtful planning and market analysis, to developing an efficient and sustainable business model that we expect will improve upon common industry pain points. To that end, our new e-commerce platform is a natural next step in our brand evolution and a reaffirmation of our one-stop-shop mission - expanding beyond our established nationwide distribution network to allow consumers to purchase their favorite items online and have them shipped directly to their home or business. This new channel allows us to dynamically change our offerings to address consumer needs, while capturing what we expect to be an incremental shopping occasion in select regions where consumers may have less convenient access to our products today."
MLSS

Hot Stocks

08:35 EST Milestone Scientific enters distribution agreement with Bioline Supply - Milestone Scientific has entered into an agreement with Bioline Supply to distribute the CompuFlo Epidural System and related disposables in Spain. Bioline is a premier distributor of medical devices and equipment, supporting many hospitals and pain clinics across Spain. In connection with the agreement, Milestone Scientific has commenced sales and shipments of its CompuFlo Epidural Instrument and consumables to Spain.
FEMY

Hot Stocks

08:34 EST Femasys completes enrollment of FemaSeed pivotal trial - Femasys announced completion of enrollment in the LOCAL FemaSeed pivotal clinical trial, designed to evaluate women undergoing FemaSeed cycles due to male factor infertility. FemaSeed, an intratubal insemination approach that delivers sperm to the fallopian tube where conception occurs is now readying for commercialization. This pivotal trial was ongoing at the time of receiving both a 510K clearance from the Food and Drug Administration in September 2023 and an approval from Health Canada in April 2023. Femasys is creating accessible innovative options for women, as exemplified with FemaSeed, now an FDA-cleared infertility treatment and its lead product candidate FemBloc in late-stage clinical development for permanent birth control. The Company is commercializing complementary diagnostic products that were internally developed through its in-house R&D and manufacturing capabilities, with regulatory approvals in the U.S., Canada and other ex-U.S. territories.
EDBL

Hot Stocks

08:34 EST Edible Garden posts over 45% y/y increase in preliminary sales for Thanksgiving - Edible Garden AG announced that the Company experienced an over 45% year-over-year increase in preliminary sales results for the Thanksgiving holiday. Jim Kras, Chief Executive Officer of Edible Garden, stated, "We are extremely proud of the Company's performance this Thanksgiving season, as evidenced by record-setting sales. Understanding the drivers of our success is key, notably our 98.5% fulfillment rate, which ranks among the industry's best. Our fulfillment rate is more than just a data point, we believe it is an indicator of Edible Garden's reliability and efficiency as a supplier."
BMRN

Hot Stocks

08:33 EST BioMarin closes reimbursement agreement with German insurance fund for Roctavian - BioMarin announced an agreement with the German National Association of Statutory Health Insurance Funds - GKV-SV - on the reimbursement amount for Roctavian for people with severe hemophilia A. This is the first gene therapy for hemophilia to receive an agreed federal price in Germany. Roctavian brings value to individuals and the healthcare system in Germany, as a one-time, single-dose therapy delivered as an intravenous infusion over 3-4 hours at a gross price of EUR28,933.53 per vial. This vial price equates to approximately $900K per patient in net revenue to BioMarin. BioMarin and GKV-SV have agreed on an outcome-based prospective cohort model for Roctavian. This agreement, with a minimum term of 3 years, ensures the supply and reimbursement for eligible patients in Germany with Roctavian by the GKV-SV. Final price negotiations with the Italian Medicines Agency are underway and expected to be formalized by year-end 2023. BioMarin continues to work with private and public payers in the U.S. to enable access. It is estimated that there are approximately 6,500 adults living with severe hemophilia A in the U.S. BioMarin expects approximately 2,500 of those adults to be eligible to receive ROCTAVIAN at this time.
RQHTF

Hot Stocks

08:32 EST Reliq Health Technologies provides update on status of MCTO - Reliq Health Technologies is providing this update on the status of a management cease trade order granted on October 31, 2023 by the British Columbia Securities Commission under National Policy 12-203 - Management Cease Trade Order. On October 31, 2023, the Company announced that, for reasons disclosed in the news release, there would be a delay in the filing of its financial statements and accompanying management's discussion and analysis for the fiscal year ended June 30, 2023 beyond the period prescribed under applicable Canadian securities laws. During the MCTO, the general investing public will continue to be able to trade in the Company's listed common shares. However, the Company's chief executive officer and chief financial officer will not be able to trade in the Company's shares. Other than as disclosed in this news release, there are no material changes to the information contained in the Default Announcement. The Company confirms that it intends to satisfy the provisions of NP 12- 203 and will continue to issue bi-weekly default status reports for so long as it remains in default of the Annual Filings requirement. The Company expects to file the Annual Filings on or before December 29, 2023, at which time the Company will issue a news release announcing the completion of the filings.
DXC NOW

Hot Stocks

08:31 EST DXC Technology, ServiceNow expand partnership - DXC Technology (DXC) and ServiceNow (NOW) have expanded their strategic partnership to transform service and workflow management for customers globally. The companies will integrate ServiceNow advanced analytics and enhanced AI capabilities from its ITSM Pro and process mining solutions into DXC Platform X, to drive new levels of innovation for joint customers. DXC, a ServiceNow Global Elite partner, is deepening the alliance by becoming a preferred partner for ServiceNow Professional Services and ServiceNow Impact, an AI-powered solution designed to help reduce client time to value and maximize return on investment. Through this partnership, DXC will deliver Enterprise Applications Value Optimization services, extending the DXC reach across Global Business Services and into Global Infrastructure Services with end-to-end services to support customers along their digital maturation journeys.
EVAX

Hot Stocks

08:31 EST Evaxion Biotech announces presentation of novel vaccine concept - Evaxion Biotech announces the presentation of its novel precision vaccine concept at the 65th American Society of Hematology, ASH, Annual Meeting, taking place in San Diego, California, from December 9-12, 2023. Selected for an Oral Presentation - Evaxion has been chosen for an oral presentation from a competitive pool of greater than5000 submitted abstracts. The presentation will unveil a breakthrough achievement using the Company's proprietary AI target discovery and development platform, AI-Immunology. Tailored Precision Vaccines - The precision vaccines are tailored to the specific tumor profiles and immune systems of patient groups. This marks a significant stride forward in addressing the complexities of cancers, including hematological malignancies.
LRHC

Hot Stocks

08:30 EST La Rosa Holdings launches multi-level revenue share plan for agents - La Rosa Holdings announced that it has launched a multi-level revenue share plan designed to empower realtors with a unique income stream. The Company believes this innovative model will provide agents with an opportunity to create passive income from day one, setting a new standard for compensation within the real estate sector. "As a publicly traded real estate company, we are not just changing the game, we're rewriting the rules. By introducing a multi-level revenue share plan that combines immediate earning potential, a four-level structure, and the flexibility of a 100% commission plan, we are paving the way for a new era in the real estate industry," commented Joe La Rosa, CEO of the Company. "As one of the first companies in the country to offer such a comprehensive and innovative compensation model, we are committed to empowering our agents and fostering a culture of success. We encourage new agents to join us on this exciting journey, where your success is not just a goal-it's a shared triumph for every member of our real estate family."
CMND SPRC

Hot Stocks

08:28 EST Clearmind announces results from weight loss, metabolic disorder program - Clearmind Medicine announced results from its pre-clinical trial led by Professor Joseph Tam from The Hebrew University of Jerusalem. The treatment used in the trial combined Clearmind's MEAI, a novel proprietary psychedelic treatment for various addictions, obesity and metabolic disorders and depression, and SciSparc's Palmitoylethanolamide, which is an anti-inflammatory agent and the active ingredient of its proprietary CannAmide. The goal of the trial was to identify the optimal dosage for their combination, to observe their safety and impact on various metabolic and behavioral parameters including fat oxidation, locomotor activity, and feeding behavior. Fourteen different treatment groups were created receiving single treatment doses ranging from 40, 20, 10, 5, 1, to 0.5 mg/kg of MEAI with or without a constant PEA dose of 25 mg/kg. MEAI administration exhibited a remarkable degree of tolerance, leaving the animals' viability unaffected across all experimental groups. Similar results were also observed in groups treated by the combination of MEAI and PEA with the most prominent effects being observed when combining MEAI and PEA, particularly at 20 and 10 mg/kg. Results indicated that: The administered treatment exhibited a remarkable degree of tolerance, leaving the mice' viability unaffected across all experimental groups. Combining MEAI and PEA, particularly at 20 and 10 mg/kg, led to increased oxygen consumption and carbon dioxide emission, coupled with elevated energy expenditure and fat oxidation. Oxygen consumption and carbon dioxide emission indicates increase in metabolic process and fat burn. A striking reduction in food consumption and meal sizes was also observed, primarily at 40 and 20 mg/kg of MEAI. Slight elevations in carbohydrate oxidation were noted, particularly at 20 and 10 mg/kg. At 40 and 20 mg/kg significant reductions in ambulation was noted, without affecting voluntary activity.
SPRC CMND

Hot Stocks

08:28 EST SciSparc announces results from weight loss, metabolic disorder program - SciSparc (SPRC) announced successful results from a pre-clinical trial performed by Professor Joseph Tam from The Hebrew University of Jerusalem. The trial was conducted as part of the collaboration between SciSparc and Clearmind Medicine (CMND). The combination treatment includes palmitoylethanolamide, an anti-inflammatory agent and the active ingredient of the Company's proprietary CannAmide, and MEAI, Clearmind's novel proprietary psychedelic treatment for various addictions, obesity, and depression. The goal of the trial was to identify the optimal dosage for the Combination Treatment and, in turn, observe the safety and impact thereof on various metabolic and behavioral parameters including fat oxidation, locomotor activity, and feeding behavior. Results indicated: The administered treatment exhibited a meaningful degree of tolerance, leaving the mice's viability unaffected across all experimental groups. Combining MEAI and PEA, particularly at 20 and 10 mg/kg, led to increased oxygen consumption and carbon dioxide emission, coupled with elevated energy expenditure and fat oxidation. The changed rates of oxygen consumption and carbon dioxide emission indicate increases in the metabolic process and fat burn. A notable reduction in food consumption and meal sizes was also observed, primarily at 40 and 20 mg/kg of MEAI. Slight elevations in carbohydrate oxidation were noted particularly at 20 and 10 mg/kg. At 40 and 20 mg/kg significant reductions in ambulation was noted, without affecting voluntary activity. "I am encouraged by the positive results from our recent pre-clinical trial, which represents another milestone in our ongoing efforts to develop safe and effective innovative therapies. The successful collaboration between SciSparc and Clearmind continues to demonstrate the potential of our Combination Treatment to address obesity and related health challenges," said Oz Adler, SciSparc's Chief Executive Officer. "The trial's findings, including increased metabolic activity, reduced appetite, and enhanced fat oxidation, are promising indicators of the treatment's efficacy and safety."
AMAM

Hot Stocks

08:26 EST Ambrx Biopharma provides update on APEX-01 - Ambrx Biopharma announced a clinical update regarding its proprietary anti-PSMA antibody drug conjugate, ADC, ARX517 in the ongoing APEX-01 Phase 1 / 2 dose escalation and dose expansion clinical trial in metastatic castration-resistant prostate cancer. Following the completion of the 21-day DLT observation period from APEX-01 dose escalation Cohort 9, no DLTs or SAEs were observed. Two of the three patients in Cohort 9 had a rapid PSA reduction of 91% and 33% at the first PSA assessment at three weeks post-treatment and following only one dose of ARX517. A PSA decrease was not reported in the third patient because the patient had non-PSA secreting mCRPC. On Monday November 27, the safety monitoring committee voted to dose escalate to 4.5 mg/kg as well as expand patients at the 3.4 mg/kg dose. All expansion cohorts, Cohort 4, Cohort 6, and Cohort 8 are now fully enrolled. "We continue to observe no DLTs or SAEs at the highest ARX517 dose tested. We believe this is a direct result of the stability of conjugation supported by PK data presented at ESMO last month. While we are opportunely positioned to explore higher doses, we have already observed significant PSA50 decline and long duration on treatment at 2.0 mg/kg," said Sandra Aung, Ph.D., Chief Clinical Officer of Ambrx. "The high interest in our PSMA-targeting ADC and pace of enrollment in the APEX-01 study has been outstanding and based on this we are anticipating to reach a recommended phase 2 dose by early next year."
SNAX

Hot Stocks

08:25 EST Stryve Foods announces major distribution expansion - Stryve Foods announces its strategic distribution expansion into several prominent retail chains, solidifying its presence in key markets. The company's innovative and protein-packed snacks will now be available at Southeastern Grocers, Cub Foods, Lunds/Byerly's, Fresh Thyme, Lowes Foods, AAFES, Holiday Oil, Timewise, Family Express, and Dash In. This expansion marks a significant milestone for Stryve Foods. "We are excited to partner with these esteemed retailers to bring Stryve's innovative snacks to even more consumers across the country," said Chris Boever, CEO at Stryve. "Our mission is to help Americans snack better, and we're doing that by providing people with convenient and significantly more nutritious snack options that support a healthy and active lifestyle. The inclusion of these retailers in our distribution network allows us to reach a broader audience and further deliver on that promise," Boever concluded.
DMK

Hot Stocks

08:23 EST DMK Pharmaceuticals regains full rights for SYMJEPI from USWM - DMK Pharmaceuticals announced that it is reacquiring the rights to its SYMJEPI Injection 0.3mg and SYMJEPI Injection 0.15mg products from USWM. US WorldMeds previously held exclusive distribution and commercialization rights for SYMJEPI and ZIMHI products in the United States, and was responsible for marketing, promotion and distribution efforts. The Company is now actively seeking out-license opportunities for SYMJEPI in the US and globally, in addition to exploring other options with a focus on maximizing value for shareholders.
DT

Hot Stocks

08:23 EST Dynatrace achieves AWS security competency - Dynatrace announced it has achieved the Amazon Web Services AWS Security Competency. By earning this competency, Dynatrace has demonstrated expertise in helping its customers proactively remediate vulnerabilities and defend against threats across their AWS environments. The Dynatrace platform's application security capabilities include runtime vulnerability analytics, providing real-time detection and prioritization of vulnerabilities that present a significant risk in production environments; runtime application protection, which detects and blocks application attacks, like SQL injection, command injection, and JNDI attacks; and security analytics, enabling threat hunting and real-time detection and incident response. These capabilities, combined with the Dynatrace platform's Davis(R) AI and extensive automation capabilities, enable customers to proactively mitigate risks and automate remediation so they can deliver innovation with confidence.
DSS

Hot Stocks

08:23 EST DSS' Premier Packaging signs contract extension with client worth up to $15M - DSS announced that its wholly-owned subsidiary, Premier Packaging, signed a contract extension with an existing client for the next three years totaling a minimum of $12 Million with a fourth year extension option bringing the potential total revenue to over $15 Million. Frank Heuszel, President and CEO of DSS, Inc., said, "We are very pleased to see that our capital investment to increase production capacity and economies of scale at Premier Packaging continues to result in satisfied clients and increasing revenues. Since inaugurating Premier's state-of-the-art 105,000 sq. ft. facility in 2021, our packaging division has expanded its customer base and built a competitive advantage in the packaging industry."
ACN SAP

Hot Stocks

08:22 EST Accenture, SAP broaden partnership to aid clients form resilient supply chains - Accenture (ACN) announced it will collaborate with SAP (SAP)to help organizations reinvent their supply chains with a comprehensive supply chain nerve center that can reduce risk, enhance visibility and support sustainability goals. Additionally, Accenture and SAP plan to co-develop new capabilities for the SAP(R) Integrated Business Planning for Supply Chain SAP IBP solution to help further enhance an organization's ability to quickly and cost-effectively respond to changes in supply, demand and inventory.
ACN SAP

Hot Stocks

08:22 EST Accenture, SAP broaden partnership to aid clients form resilient supply chains - Accenture (ACN) announced it will collaborate with SAP (SAP)to help organizations reinvent their supply chains with a comprehensive supply chain nerve center that can reduce risk, enhance visibility and support sustainability goals. Additionally, Accenture and SAP plan to co-develop new capabilities for the SAP(R) Integrated Business Planning for Supply Chain SAP IBP solution to help further enhance an organization's ability to quickly and cost-effectively respond to changes in supply, demand and inventory.
PHAT

Hot Stocks

08:21 EST Phathom Pharmaceuticals announces commercial availability of VOQUEZNA - Phathom Pharmaceuticals announced the U.S. commercial availability of VOQUEZNA. VOQUEZNA is now available for the treatment of adults with Erosive Esophagitis, also known as Erosive GERD, and the relief of heartburn associated with Erosive GERD. As the first and only approved potassium-competitive acid blocker in the U.S., this milestone brings the power of a new class of acid suppression treatment to a disease with high unmet need. "We are thrilled to announce the commercial availability of our first-in-class medication, VOQUEZNA, now available for the millions of people in the U.S. suffering from Erosive GERD," said Martin Gilligan, Chief Commercial Officer at Phathom Pharmaceuticals. "For over three decades, there has been no major innovation in this category. We are excited to introduce VOQUEZNA to patients and healthcare providers, as it has been shown to provide rapid, potent, and durable acid suppression and has the power to help heal Erosive GERD for patients seeking a new and effective treatment option."
TRU CMCSA

Hot Stocks

08:21 EST TransUnion, FreeWheel expand partnership to improve audience match rates - TransUnion announced an expanded partnership with FreeWheel. The partnership integrates TransUnion's TruAudience Data Marketplace with FreeWheel's Audience Manager. The result is a new solution that allows publishers and programmers in the TV ad ecosystem to greatly improve their audience match rates. It does this by leveraging the FreeWheel Identity Network to better pair TransUnion audience segments with FreeWheel's inventory sources.
NUWE

Hot Stocks

08:20 EST Nuwellis announces new real-world data on Aquadex ultrafiltration therpay - Nuwellis announced new real-world data demonstrate that pediatric patients with fluid overload respond well to Aquadex ultrafiltration therapy with continuous hematocrit monitoring. The publication, "Using Aquapheresis with Continuous Hematocrit Monitoring to Guide Ultrafiltration," was featured in Pediatric Nephrology. The publication is a single-center case study review of pediatric patients with hypoalbuminemia and severe fluid overload. Patients were treated with Nuwellis' Aquadex ultrafiltration therapy with continuous hematocrit monitoring to guide isotonic fluid removal. The study concluded that the therapy successfully treated small patients without hemodynamic instability or other complications, demonstrating that Aquadex is an effective treatment option for fluid overload. "We're proud to share new evidence supporting the clinical need and applications for Aquadex among pediatric patients, and we're grateful to Dr. Michelle Starr and her colleagues for their trust and confidence in our therapy," said Nestor Jaramillo, Jr., President and Chief Executive Officer of Nuwellis. "Our proprietary hematocrit sensor which is incorporated into the Aquadex console was a result of physician feedback and observations from clinical studies that drove us to make our Aquadex therapy even smarter. Our team is committed to supporting diuretic-resistant patients broadly, and I'm encouraged to see data validating this strategy as Nuwellis works to expand access to ultrafiltration to even more patients and clinicians."
RWLK

Hot Stocks

08:19 EST ReWalk demonstrates AI autonomous decision making in exoskeleton prototype - ReWalk Robotics announced the demonstration of a proof-of-concept next-generation exoskeleton. As part of the Israel Innovation Authority's MAGNET incentive program, the Human Robot Interaction Consortium, the company has reached a milestone by integrating advanced sensing technologies and artificial intelligence to enable autonomous decision making in the Company's latest exoskeleton prototype. The MAGNET incentive program provides R&D and collaboration grants to private businesses and leading academic centers. The goals of the HRI Consortium are to "develop advanced technologies aimed at providing robots with social capabilities, enabling them to carry out various tasks and effective interactions with different users in diverse operational environments." The Consortium seeks to develop a Human-Robot Interaction Toolkit for Robot Operating Systems which could potentially yield income to contributing members.
ERAS

Hot Stocks

08:19 EST Erasca achieves key milestones for naporafenib, ERAS-801 - Erasca announced program updates for pan-RAF inhibitor naporafenib and central nervous system-penetrant EGFR inhibitor ERAS-801, as well as a strategic program prioritization that extends its projected cash runway from H2 2025 to H1 2026. Recent Program Updates: Naporafenib Plus Trametinib for Patients with NRAS mutant Melanoma in Pivotal SEACRAFT-2 Trial. End of Phase 2 meetings with U.S. Food and Drug Administration and European health authorities confirm SEACRAFT-2 Phase 3 trial design and provide clarity on registrational pathway: Enrollment of patients with high unmet medical need who progressed on, or are intolerant to, standard of care immune checkpoint inhibitor therapy; Comparator arm is physicians' choice of cytotoxic chemotherapy or trametinib; Dual primary endpoint evaluation of progression free survival and overall survival, with PFS acceptable for potential initial approval; The Phase 3 trial consists of two stages: a randomized, controlled, dose optimization stage, for which we expect to have a data readout in 2025, and a randomized, controlled stage to support regulatory approval; Phase 3 SEACRAFT-2 trial initiation remains on track for H1 2024. ERAS-801 for Patients with Recurrent GBM in Phase 1 THUNDERBBOLT-1 Trial: MTD identified as 240 mg once a day and MTD-1 identified as 160 mg QD for ERAS-801; ERAS-801 was safe and tolerable at the MTD and MTD-1 dose levels; ERAS-801 exhibited well behaved pharmacokinetic characteristics; Expansion cohorts actively enrolling to collect additional safety, tolerability, and preliminary efficacy data to support dose optimization and selection; Phase 1 dose escalation data to be presented at a scientific meeting in H1 2024; expansion cohort data are anticipated in H2 2024. Prioritized Clinical Programs and Key Upcoming Milestones: Naporafenib - Pan-RAF Inhibitor: Dosing of the first patient in pivotal Phase 3 SEACRAFT-2 trial in patients with NRASm melanoma expected H1 2024; Initial signal-seeking Phase 1b efficacy data in relevant tumor types from patients with RAS Q61X solid tumors in ongoing SEACRAFT-1 trial expected between Q2-Q4 2024. ERAS-801 - CNS-penetrant EGFR Inhibitor: Phase 1 monotherapy dose escalation and expansion data in rGBM expected in 2024. ERAS-007 - ERK1/2 Inhibitor: Initial dose expansion data from Phase 1b/2 HERKULES-3 trial further evaluating encouraging early efficacy data with ERAS-007 in combination with EC in EC-naive patients with BRAF mutant CRC expected between H2 2023 and H1 2024. Deprioritized Opportunities: Select trials or programs were deprioritized, despite their potential differentiation, to focus the company's resources on the most promising programs, which is expected to extend the company's cash runway from H2 2025 to H1 2026: FLAGSHP-1 - Phase 1b combination trial of ERAS-601 SHP2 inhibitor with cetuximab was deprioritized. Though ERAS-601 achieved confirmed responses as a monotherapy and in combination with cetuximab, preliminary data do not justify further development of this combination in FLAGSHP-1 indications; ERAS-5 - Preclinical ULK inhibitor; ERAS-10 - Preclinical protein degrader
SGMT

Hot Stocks

08:17 EST Sagimet Biosciences announces presentation on FASN inhibitor results - Sagimet Biosciences will present preclinical data at the 7th Obesity and NASH Drug Development Summit on November 28, 2023, in Boston. The presentation details an evaluation of Sagimet's FASN inhibitor alone or in combination with semaglutide in a preclinical mouse model of nonalcoholic steatohepatitis, using an artificial intelligence based digital pathology platform to assess fibrosis. "We are pleased to report strong preclinical combination results demonstrating that the FASN inhibitor alone, not semaglutide, was responsible for significant reduction of liver fibrosis, a predictor of outcome in NASH," said Eduardo Bruno Martins, M.D., D.Phil., Sagimet's Chief Medical Officer. "Building upon the preclinical data presented at AASLD - The Liver Meeting earlier this month, our oral presentation includes transcriptomic profiling analysis which suggests that the FASN inhibitor and semaglutide combination not only has an additive effect but also provides distinct MOAs that could potentially benefit patients living with NASH and dysmetabolic syndrome. We believe that these preclinical data support further clinical evaluation. Our immediate focus remains on advancing denifanstat as a potential monotherapy and we remain on track to report topline results of our FASCINATE-2 Phase 2b clinical trial, including biopsy data, in the first quarter of next year."
TWKS

Hot Stocks

08:17 EST Thoughtworks to expand business to Switzerland - Thoughtworks announced it is expanding its business to Switzerland. This is part of Thoughtworks' plan to scale up in industry verticals in the European region. Thoughtworks currently serves financial and health services clients and also works with companies like SMG Swiss Marketplace Group, a network of online marketplaces and V-Zug, a worldwide operating manufacturer of household appliances.
LCFY

Hot Stocks

08:16 EST Locafy announces first trial results from preliminary article accelerator - Locafy announced trial results from its first technology implementations from its partnership with the U.S.-based media publisher previously announced on June 22, 2023. These trials measured several key metrics, including impression and visitor counts, number of keywords for which articles ranked, and click-through-rate. After reviewing data taken directly from the client's Google Search Console, Article Accelerator generated significant impacts within 30 days, including increases of up to 71% in both impression and visitor counts and up to a 193% increase in the volume of keywords for which the articles rank in Google search results, all while maintaining or growing CTR. "Based on our successful initial trials, we believe that Article Accelerator has demonstrated that it can impact individual articles in highly competitive industries and markets," said Locafy CEO Gavin Burnett. "Media organizations have traditionally generated millions in revenue from their clients paying to promote their businesses within a recognized online news or magazine brand. For these sellers hoping to compete in a saturated content market, harnessing a broad audience is critical to generating interest and driving growth."
M

Hot Stocks

08:15 EST Macy's names Sharon Otterman CMO, starting on Monday, December 11 - Macy's (M) announced that Sharon Otterman has been named chief marketing officer of Macy's. Sharon will begin leading the company's marketing organization starting on Monday, December 11, reporting to Tony Spring, president and CEO-elect, Macy's. In this role, Sharon will lead Macy's strategic marketing, spearheading the company's brand evolution and build awareness, engagement, and loyalty amongst all customer segments... Sharon has more than 25 years of experience leading marketing and transforming brands for Fortune 500 companies across entertainment, media, and sports industries. Most recently, Sharon served as CMO at Caesars Entertainment, where she launched Caesars Sportsbook, a new sports betting brand in the U.S., and enhanced the sports betting and gaming brand experience. Prior to Caesars Entertainment, she served as EVP and CMO at Madison Square Garden Company, was CMO for NBCUniversal's News Division, and was also the VP of marketing at ESPN. Earlier in Sharon's career, she pioneered creative and media campaigns at top advertising agencies. Sharon has a B.S. in Corporate Communications from Ithaca College and graduated from the Executive MBA Program at New York University.
TMO

Hot Stocks

08:14 EST Thermo Fisher, Flagship form strategic partnership - Thermo Fisher and Flagship announced the formation of a strategic partnership to develop and commercially scale multiproduct platforms on an accelerated basis. Through this collaboration, Thermo Fisher and Flagship will work together to create new platform companies focusing on novel tools and capabilities that seek to power the biotech ecosystem and accelerate the development of first-in-class therapies. The newly formed strategic partnership is an expansion of the long-standing supply relationship between Thermo Fisher and Flagship, which extends to Flagship's ecosystem of companies and leverages the expertise of both organizations including the areas of life science tools, diagnostics, and services.
KULR

Hot Stocks

08:14 EST KULR Technology secures follow-on defense contract from DoD contractor - KULR Technology Group announced the receipt of a follow-on contract from a leading Department of Defense contractor for advanced thermal management systems in a next-generation air-to-air missile program. This contract signifies KULR's expanding position in the defense sector as the Company anticipates consistent demand for its solutions through 2030, opening avenues for additional opportunities in similar fields. The multi-year follow-on engagement has an estimated total contract value to KULR of over $8 million.
CATX

Hot Stocks

08:13 EST Perspective Therapeutics announces first human SPECT imaging of Pb-212 - Perspective Therapeutics announced the publication of the first human SPECT images utilizing the alpha-emitting isotope of 212Pb, which was labeled to the Company's proprietary theranostic VMT-alpha-NET product. The imaging was conducted as part of a series of four neuroendocrine tumor patients who were administered VMT-alpha-NET at a clinical study site in Germany. The Company is developing VMT-alpha-NET for the treatment and diagnosis of somatostatin receptor subtype 2-expressing neuroendocrine tumors. VMT-alpha-NET is being administered under the supervision of Prof. Dr. Jorg Kotzerke, Director of the Department of Nuclear Medicine at the Technical University of Dresden in Germany. The patient received 90 MBq of VMT-alpha-NET intravenously, and whole-body scintigraphy and SPECT/CT images were acquired 2 hours, 5 hours, and 19 hours after injection. Images were collected on a Symbia Intevo T6 using a high-energy collimator. The SPECT/CT images showed high accumulation of VMT-alpha-NET in liver metastases and were consistent with the previously acquired DOTATATE PET/CT. High tumor retention can be observed in the planar and SPECT/CT images over time. As expected, due to the short half-life of 212Pb, the images acquired after 19 hours showed a high level of noise due to the low count statistics. The patient showed no early or acute side effects. Under certain expanded access circumstances, VMT-alpha-NET may be made available to qualified doctors in some countries. Perspective Therapeutics supplies a generator, drug precursors and isotopes for the local production of its proprietary radiotherapeutic, VMT-alpha-NET. Dr. Kotzerke and his team will continue to monitor patients' progress over the coming months. The publication is entitled "First-in-human SPECT/CT imaging of Pb-VMT-alpha-NET in a patient with metastatic neuroendocrine tumor". It follows a similar publication in Clinical Nuclear Medicine from earlier this year showing successful SPECT imaging of Perspective's surrogate diagnostic isotope 203Pb which was also linked to VMT-alpha-NET. Recruitment is ongoing for the use of VMT-alpha-NET in imaging and therapeutic trials at leading U.S. institutions. VMT-alpha-NET is categorized as an investigational new drug by the U.S. Food and Drug Administration. The use of VMT-alpha-NET in qualifying expanded access situations is entirely separate from and outside the scope of the Company's Phase 1 trial.
ICAD GEHC

Hot Stocks

08:12 EST iCAD announces AI solutions to be offered in new MyBreastAI offering - iCAD (ICAD) announced that key artificial intelligence, AI, powered solutions from iCAD's ProFound Breast Health Suite are the first applications to be offered in GE HealthCare's (GEHC) new MyBreastAI Suite offering. "iCAD has been collaborating with GE HealthCare for more than 20 years and this latest offering is a powerful affirmation of our shared mission to advance breast health," said Dana Brown, President and CEO of iCAD, Inc. "Our ProFound AI DBT technology is a cornerstone of AI-enabled solutions and is now offered as part of GE HealthCare's MyBreastAI Suite to seamlessly deploy AI to breast imaging workflow to help enhance the detection and diagnosis of breast cancer while optimizing workflow efficiency to ultimately, help elevate patient care outcomes globally." The first three AI applications to be offered as part of the initial release include the following solutions from iCAD: ProFound Detection, AI for Digital Breast Tomosynthesis; SecondLook for 2D Mammography; PowerLook Density Assessment;
FOR DHI

Hot Stocks

08:12 EST Forestar Group CEO Daniel Bartok to retire, Anthony Oxley to succeed - Forestar Group (FOR) announced the retirement of Daniel Bartok and the appointment of Anthony Oxley as president and CEO, effective January 1. Oxley will join the company from D.R. Horton (DHI), where he currently serves as senior VP - business development. Bartok will support Forestar in a consulting role for an extended period to ensure a transition.
CSLLY ARCT

Hot Stocks

08:12 EST CSL's and Arcturus Therapeutics' mRNA vaccine for COVID approved in Japan - CSL (CSLLY) and Arcturus Therapeutics (ARCT) announced that Japan's Ministry of Health, Labor and Welfare granted approval for ARCT-154, a self-amplifying mRNA COVID-19 vaccine for initial vaccination and booster for adults 18 years and older. The approval is based on positive clinical data from several ARCT-154 studies. CSL's vaccine business, CSL Seqirus, one of the largest influenza vaccine providers in the world, partnered exclusively with Meiji Seika Pharma for distribution of the sa-mRNA COVID vaccine, ARCT 154, in Japan.
FRSH FFIV

Hot Stocks

08:10 EST Freshworks appoints Yamamoto as Chief Customer, Marketing Officer - Freshworks (FRSH) announced the appointment of Mika Yamamoto as the company's Chief Customer and Marketing Officer. She will be responsible for leading the company's global marketing and customer experience teams. Yamamoto comes to Freshworks from F5 (FFIV) where she most recently served as the Executive Vice President and the Chief Marketing and Customer Engagement Officer, and led the company's data, marketing, digital transformation, and customer experience efforts across all products, segments, channels, and geographies.
JETMF

Hot Stocks

08:10 EST Global Crossing Airlines establishes UrbanX Air subsidiary - Global Crossing Airlines Group announced the creation of UrbanX Air, a wholly-owned subsidiary of GlobalX to pioneer the integration of Urban Air Mobility in South Florida. In conjunction with this announcement, GlobalX Chairman and CEO, Ed Wegel has appointed Lucy Morillo, Esq., as President and CEO of UrbanX. Morillo is responsible for leading UrbanX's launch and further developing the UAM ecosystem in South Florida. She is a member of the Wings Club; the Florida Department of Transportation Advanced Air Mobility Advisory Committee; the International Aviation Womens Association; and EVE's Air Mobility Advisory Board. Morillo is working with local and state officials, infrastructure, energy and technology providers to ensure the appropriate framework is in place. GlobalX will leverage its extensive aviation operation and knowledge to assist Morillo and UrbanX in developing and operating the UAM market in South Florida.
AMS

Hot Stocks

08:09 EST American Shared Hospital's GK Financing announces upgrading at GKCE - GK Financing announced that it has demonstrated its continued commitment in Ecuador by completing the installation of a new state-of-the-art Elekta Gamma Knife ICON at the Company's wholly owned Gamma Knife Center, GKCE. The first patient was treated successfully on November 14, 2023, after completion of clinical acceptance. The total downtime for removal, installation and acceptance testing took just six weeks to perform. Gamma Knife ICON includes a variety of innovations now available in a single platform, including offering clinicians the option of performing frameless or frame-based immobilization workflows with the Leksell headframe, both of which provide superior visualization. Peter Gaccione, CEO of American Shared Hospital Services and Board Member of GKCE, said, "We are so pleased to provide this latest advanced treatment technology to our Center in Ecuador. The Gamma Knife ICON offers more clinical throughput, features, and benefits to patients, such as faster treatment times, masked-based immobilization, and same day CT Imaging and treatments when applicable. These expanded options will benefit our patients in Ecuador in their fight against cancer."
ARE LLY

Hot Stocks

08:08 EST Alexandria Real Estate selected for Eli Lilly's Gateway Labs in San Diego - Alexandria Real Estate (ARE) announced an exclusive partnership with Eli Lilly (LLY) to expand Lilly's Gateway Labs model to the San Diego life science cluster. Launched in 2019 by Lilly in the San Francisco Bay Area, Gateway Labs is a shared innovation accelerator designed to speed the discovery of innovative medicines by providing emerging biotechnology companies with mission-critical, flexible laboratories and essential, integrated nontechnical space; opportunities to collaborate with Lilly; and access to capital through Lilly and its venture network. Expected to open in the first half of 2024, the Lilly Gateway Labs San Diego site will feature flexibly designed move-in-ready laboratories and fully integrated nontechnical space.
CRS

Hot Stocks

08:08 EST Carpenter Technology appoints Malloy as COO, VP Graf to leave company - Carpenter Technology Corporation announced Brian Malloy has been named Senior Vice President and Chief Operating Officer, COO, effective December 4, 2023. In this position, Malloy will expand his responsibilities and oversee the operations of Carpenter Technology's Specialty Alloys Operations and Performance Engineered Products business segments. He will continue to report directly to Tony Thene, President and Chief Executive Officer. Mr. Malloy currently serves as Senior Vice President and Group President of the SAO business segment. Additionally, David Graf, Vice President, VP, and Group President of the PEP business segment, will be leaving the Company to pursue other opportunities.
PDD

Hot Stocks

08:07 EST PDD Holdings jumps 14% after Q3 earnings beat - Shares of PDD Holdings, the owner of online shopping platform Temu, are up 14% or $16.73 at $134.62 in pre-market trading after the company reported better than expected Q3 earnings and revenue.
KRRO

Hot Stocks

08:07 EST Korro Bio appoints Meyers to board of directors - Korro Bio announced the appointment of Rachel Meyers, PhD, to the Company's Board of Directors. Most recently, Dr. Meyers served as Chief Scientific Officer of Faze Medicines.
BIMI

Hot Stocks

08:06 EST BIMI International Medical announces buyback of warrants - BIMI International Medical announced its entry into material definitive agreements with certain of its warrant holders, pursuant to which BIMI agreed to buy back an aggregate of 7,066,913 warrants to purchase shares of common stock of the Company from these warrant holders. BIMI agreed to pay $0.30 for each share of common stock underlying the warrant, or an aggregate purchase price of $2,120,073.80 to the warrant holders within three business days, or two months, of the signing of the agreements. The warrants will be deemed cancelled upon the receipt by the sellers of the purchase price.
APLD

Hot Stocks

08:06 EST Applied Digital to host ribbon-cutting ceremony at Texas facility - Applied Digital Corporation announced the Company will be hosting a ribbon-cutting ceremony celebrating the energizing of its 200-megawatt facility in Garden City, Texas on December 6, 2023. Garden City officials will join leadership from Applied Digital to support the landmark opening of the facility. "We are grateful to the local Garden City community for the support, time, and dedication put into this facility," said CEO of Applied Digital, Wes Cummins. "We are proud to celebrate the energization of this datacenter. This is a testament to our commitment to providing digital infrastructure solutions for high-performance computing that redefines traditional data centers, including our existing blockchain hosting operations and other HPC applications."
AWH

Hot Stocks

08:06 EST Aspira Women's Health secures reimbursement for Ova1Plus from Medi-Cal - Aspira Women's Health announced that California Medicaid added Ova1Plus to its fee schedule. Aspira will be reimbursed at a rate of $897 for all Ova1Plus tests processed for Medi-Cal patients meeting applicable coverage requirements beginning immediately and going back to date of service back to October 15, 2023. The California Department of Health Care Services who is responsible for establishing policy and covered health care services for the California Medicaid program, inclusive of both the fee-for-service and managed care delivery systems has added the Ova1Plus CPT 81503 to its Provider Manual and fee schedule at the Medicare rate of $897.
ACRV

Hot Stocks

08:05 EST Acrivon Therapeutics announces FDA has granted BDD for ACR-368 - Acrivon Therapeutics announced the U.S. Food and Drug Administration, FDA, has granted Breakthrough Device designation, BDD, for the ACR-368 OncoSignature assay, a multiplex immunofluorescence assay for the identification of ovarian cancer patients who may benefit from ACR-368 treatment. The designation reflects FDA's determination that the device is reasonably expected to provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions. "We are pleased that our ACR-368 OncoSignature assay, developed specifically to predict tumor sensitivity to ACR-368 and used in our ongoing registrational-intent clinical study to treat patients based on OncoSignature-predicted sensitivity, has been designated by the FDA as a Breakthrough Device," said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics. "It is exclusively through our proprietary AP3 platform that we are able to develop these proteomic-based assays that are designed to predict the patients most likely to benefit from treatment with our drug candidates. We believe this designation is the first of its kind for such an assay, and represents yet another powerful validation of our AP3 platform. The designation importantly also highlights meaningful potential value to patients as we continue to progress ACR-368 in the clinic."
ICCM

Hot Stocks

08:04 EST IceCure Medical's ProSense System shows high efficacy in kidney cancer tumor - IceCure Medical's ProSense System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, demonstrated safety and efficacy in a series of independent studies of ProSense(R) published in peer-reviewed journals. The study published in Cancers demonstrated the safety and efficacy of ProSense in treating malignant small renal masses. ProSense is approved for the treatment of benign and malignant kidney tumors in the U.S., Europe, and numerous other countries. A total of 25 patients underwent cryoablation for 26 T1a renal tumors. Disease-free survival rate was 92% - 23 out of 25 - at a median follow-up of 26 and a half months. Recurrent lesions were treated again using cryoablation, achieving a secondary local control rate of 100%. No patients died, no major complications arose. 92.4% of were discharged the day after surgery.
WKSP

Hot Stocks

08:04 EST Worksport announces COR system to be assembled in Canada - Worksport announces that the COR battery system will be designed, developed, and assembled in Canada, combining domestic and international components. Worksport has recently formed a strategic partnership with a prominent Canadian manufacturer specializing in electronic boards. This key collaboration will see the partnering manufacturer assembling the full COR unit in Canada, including the electronic boards for the COR inverter and hub. Together with Worksport, they will implement a rigorous quality control process to ensure the highest quality standards. This significant move follows closely on the heels of Worksport's announcement regarding the upcoming Alpha Release of the COR battery system. The Alpha Release, which will allow for real-world testing and first-hand user experiences, is a pivotal step towards official market launch. Furthermore, as Worksport continues to ramp up production of its hard-folding and soft-folding tonneau covers to meet the increased demand, spurred by the recently announced $16 million annual sales agreement, the Company remains dedicated to delivering top-quality solutions to its valued customers.
EFTR

Hot Stocks

08:03 EST eFFECTOR Therapeutics receives Fast Track Designation for zotatifin combination - eFFECTOR Therapeutics announced that the U.S. Food and Drug Administration has granted Fast Track designation for zotatifin in combination with fulvestrant and abemaciclib as second- or third-line therapy for the treatment of adult patients with estrogen receptor-positive/human epidermal growth factor-negative advanced or metastatic breast cancer with disease progression following treatment with endocrine therapy and a CDK 4/6 inhibitor. The Fast Track designation was granted following FDA review of preclinical and clinical data for zotatifin, including recent safety and efficacy data for the ZFA triplet. Zotatifin is being investigated in a Phase 1/2 dose escalation and expansion study, with cohorts currently enrolling in ER+/HER2- breast cancer. Data presented at the 2023 meeting of the American Society of Clinical Oncology showed that, in heavily pretreated patients, five out of 19 RECIST-evaluable patients achieved a partial response, including four confirmed and one unconfirmed. All five patients who achieved a PR had previously progressed on prior CDK 4/6 and fulvestrant treatments, and all five had received one or more prior lines of chemotherapy in the metastatic setting. Based on safety and tolerability results to date, dose escalation was resumed in combination with fulvestrant. Further updates to interim data from the ZFA triplet cohort and resumed dose escalation cohorts will be presented as a poster at SABCS on Friday, December 8, 2023.
PCG

Hot Stocks

08:01 EST PG&E reinstates common stock dividend - PG&E announced the company is declaring a cash dividend on its common stock for the first time since 2017. Reinstating the common dividend reflects Pacific Gas and Electric Company's substantial progress in becoming a safe and stable utility that can now attract more long-term investors. The reinstatement of the common stock dividend does not impact customer rates or bills. PG&E Corporation declared a regular quarterly cash dividend on its common stock of 1c per share. The dividend is payable on January 15, 2024, to shareholders of record as of December 29, 2023. Moving forward, PG&E Corporation expects to pay a common stock dividend to shareholders every quarter from its net income.
BTTX

Hot Stocks

07:52 EST Better Therapeutics strengthens financials with amendment to debt, costs - Better Therapeutics disclosed several initiatives aimed at extending the company's cash runway sufficiently to demonstrate commercial traction with its lead product, AspyreRx. The company launched AspyreRx in October of this year, after receiving U.S. Food and Drug Administration FDA authorization in July for the treatment of adults with type 2 diabetes. Better Therapeutics successfully negotiated an amendment to its debt facility with Hercules Capital, granting the company the opportunity to extend the Interest Only IO period until mid-2024, redeem up to $2.5M of debt without prepayment penalties, and potentially eliminate the minimum cash covenant. The amendment also grants the Company an option to convert a portion of the debt into equity, under certain conditions. In addition, to further strengthen its financial position and maintain investments to support the commercial launch of AspyreRx, the company is implementing various cost-saving measures, including company-wide salary reductions for the first quarter of 2024. These measures, along with other operational plans, are expected to improve the company's financial position by approximately $5M through the first quarter of 2024. Frank Karbe, President and Chief Executive Officer at Better Therapeutics, expressed confidence in the company's trajectory, stating, "We recognize the importance of prudent financial management and are confident that these measures will position Better Therapeutics for sustained success. With healthcare providers now prescribing AspyreRx and patients actively undergoing treatment, we expect to be able to demonstrate commercial traction over the next few months. In parallel, we continue to advance partnering discussions and evaluate all financing options available to us."
ETRGF

Hot Stocks

07:49 EST Entourage Health anticipates realizing larger savings, improved cost structures - The company said,Entourage is amid a successful and ongoing financial turnaround, marked by strategic decision-making and adaptive measures. Building on a comprehensive analysis of our business operations throughout the past year, the Company executed a progressive exit from cultivation. This pivotal move has streamlined operations and yielded significant annualized cost savings. A disciplined approach to inventory management and portfolio repositioning around select market segments have aligned the Company with the distribution of quality products and strong brands. Through these initiatives, Entourage anticipates realizing larger savings, improved cost structures and accretive margins, prioritizing improved profitability. These advancements are poised to positively impact the Company's performance, signalling a promising outlook in 2024. Entourage continues to work towards the achievement of the full-year plan. The Company's success is driven by the dedication of our exceptional team members, combined with the ever-growing demand for our products, positioning us as leaders in the cannabis industry."
PXS

Hot Stocks

07:46 EST Pyxis Tankers to acquire dry bulk vessel for $26.625M - Pyxis Tankers entered into a definitive agreement with an unaffiliated third party to purchase an 82,013 dwt dry bulk vessel built in 2015 at Jiangsu New Yangzi Shipbuilding. The eco-efficient Kamsarmax, fitted with a ballast water treatment system and scrubber, has a purchase price of $26.625 million which is expected to be funded by a combination of bank debt and cash. It is anticipated that the acquisition, which is subject to customary closing conditions, will be completed by February, 2024.
ARWR

Hot Stocks

07:39 EST Arrowhead files for clearance to begin study of ARO-DM1 for DM1 treatment - Arrowhead Pharmaceuticals announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-DM1, the company's investigational RNA interference RNAi therapeutic being developed as a potential treatment for type 1 myotonic dystrophy DM1 the most common adult-onset muscular dystrophy. ARO-DM1 is designed to reduce expression of the dystrophia myotonica protein kinase DMPK gene. There is currently no approved disease-modifying therapy for DM1. Treatments have focused on symptomatic management, including physical therapy, exercise, ankle-foot orthoses, wheelchairs, and other assistive devices. James Hamilton, M.D., MBA, Chief of Discovery and Translational Medicine at Arrowhead, said: "ARO-DM1 is Arrowhead's second clinical candidate utilizing our TRiM platform to deliver RNAi therapeutics to skeletal muscle. Patients with DM1 have muscle weakness and wasting, myotonia, cataracts, and often develop cardiac conduction abnormalities and may become physically disabled and have a shortened life expectancy. ARO-DM1 represents a novel approach to treat DM1 by silencing aberrantly transcribed DMPK mRNA, which could lead to improvements in multiple symptoms, including muscle strength and function." An application for approval of the clinical trial was submitted to a local Ethics Committee and to the New Zealand Medicines and Medical Devices Safety Authority for review by the Standing Committee on Therapeutic Trials. Pending clearance, Arrowhead intends to proceed with ARODM1-1001, a Phase 1/2a dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-DM1 in up to 48 subjects with DM1.
LQR

Hot Stocks

07:38 EST LQR House announces effective date for 1-for-60 reverse stock split - LQR House is implementing a 1-for-60 reverse stock split of its common stock, with an effective date of 12:01 a.m., Eastern Time, on November 30, 2023. In response to a written notification from the Listing Qualifications Staff of the Nasdaq Stock Market on October 24, 2023, indicating non-compliance with the minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Capital Market, LQR House's Board of Directors, in conjunction with a unanimous decision from the majority shareholders, has approved the reverse stock split as a strategic measure to address this concern. Upon the reverse stock split taking effect, every sixty issued and outstanding shares of common stock will be consolidated into one share of common stock. The common stock will commence trading on a split-adjusted basis on The Nasdaq Capital Market under a new CUSIP number at the market open on November 30, 2023. The reverse stock split aims to bring LQR House into compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). However, it is important to note that there is no guarantee that the Company will meet the minimum bid price requirement.
NVCR

Hot Stocks

07:38 EST Novocure to reduce workforce by 13% in strategic restructuring - Novocure announced a series of actions in an effort to strengthen and optimize business operations to support near-term growth drivers and long-term value creation. The plan includes an expected reduction in residual operating expenses of approximately $60M. Novocure continues to focus resources on its global commercial infrastructure and launch preparation ahead of its anticipated indication in metastatic non-small cell lung cancer and on research and development programs. Novocure continues to invest in launch readiness, including field-based commercial and field-based medical team hiring, for the anticipated approval of Tumor Treating Fields therapy for the treatment of metastatic non-small cell lung cancer following progression on or after platinum-based therapies. Novocure will deliver two phase 3 randomized clinical trial readouts in brain metastases from non-small cell lung cancer, or METIS, and locally advanced pancreatic cancer anticipated in 2024. Novocure has prioritized development investments on a sharply focused list of randomized clinical trials - TRIDENT, KEYNOTE D58 and LUNAR-2 - which have the potential to drive the greatest value in solid tumors where Tumor Treating Fields therapy has established efficacy. Novocure's plan to reduce residual operating expenses by approximately $60M includes a planned reduction in headcount of approximately 200 colleagues, 13% of its current workforce. Field-based commercial and field-based medical employees are minimally affected. Novocure expects to incur one-time costs related to the workforce reduction of approximately $7M in the fourth quarter of 2023. The anticipated cost savings are expected to offset growth investments and accelerate Novocure's path to profitability.
NLSP

Hot Stocks

07:37 EST NLS Pharmaceutics elects Florence Allouche Aknin, Claudio Basetti to board - NLS Pharmaceutics announced that, subject to final approval of the extraordinary general meeting taking place on December 22, 2023, the Company's board of directors has elected Dr. Florence Allouche Aknin and Dr. Claudio Basetti to join the Board effective January 1, 2024. Aknin, PharmD, MBA, is a professor at University Paris City, specializing in pharmaceutical innovation, entrepreneurship and fundraising. Bassetti, MD, is the Chair, Neurology Department, Inselspital, Bern University Hospital and Dean, Medical Faculty, University of Bern, focused on sleep disorders.
TFPM

Hot Stocks

07:35 EST Silver X announces restructuring of royalty for gross proceeds of $2.42M - Silver X Mining announced that Silver X and Maverix Metals, a subsidiary of Triple Flag Precious Metals, have entered into an agreement amending the terms of the original royalty agreement between the parties to, among other things, expand the royalty to cover the entire Tangana Mining Unit in the Nueva Recuperada Mining District in Central Peru. Royalty Restructuring: The prior 3.0% NSR royalty, which covered only a portion of the Mine, will be replaced by a more comprehensive 3.0% NSR royalty that spans the entire Mine. Purchase Agreement: Triple Flag will pay an aggregate consideration of $2,420,000 to be comprised of $1,670,000 of cash and an offset of amounts to be paid under the royalty agreement through the end of 2023. Strategic Rights Secured: Triple Flag has also been granted both a Right of First Refusal and a Right of First Offer over future royalty or stream-like financings, highlighting Triple Flag's confidence in the long-term value and potential of the Mine.
AYRWF

Hot Stocks

07:33 EST Ayr Wellness opens AYR Dispensary Dayton - AYR Wellness announced the opening of AYR Dispensary Dayton, the third AYR location in Ohio and first in the Dayton Metropolitan Region. The new location closely follows the recent openings of AYR Woodmere, in the Greater Cleveland Region, and AYR Goshen, in Greater Cincinnati. AYR has the future right to ownership of all three dispensaries, subject to regulatory approval.
NNXPF

Hot Stocks

07:32 EST NanoXplore receives TSX approval for normal course issuer bid - NanoXplore announced that the Toronto Stock Exchange has approved the Corporation's request to adopt a normal course issuer bid program, through which NanoXplore may purchase, for cancellation, up to 5,936,205 common shares or approximately 5% of the public float. The Corporation may purchase shares under the NCIB over a period of twelve months commencing on December 1, 2023 and ending November 30, 2024, when the bid expires. NCIB purchases are through the facilities of the TSX and certain Canadian Alternative Trading Systems and the price for any repurchased shares will be the prevailing market price at the time of the acquisition. All common shares purchased by the Corporation will be cancelled. The number of shares repurchased on any given day may not exceed 14,011 common shares, which is equal to 25% of the average daily trading volume on the TSX for the six-month period ending October 31, 2023 except where purchases are made in accordance with the "block purchase exception" of the TSX rules. The average daily volume for this period was calculated in accordance with the rules of the TSX and is equal to 56,045 common shares. The Corporation's Board of Directors believes that the purchase by the Corporation of its own common shares may, in appropriate circumstances, be a responsible investment of funds on hand. The extent to which NanoXplore repurchases its shares and the timing of such repurchases will depend upon market conditions and other corporate considerations, as determined by NanoXplore's management team. The Corporation will use funds from its existing cash balances to purchase the shares.
PDSB

Hot Stocks

07:31 EST PDS Biotechnology appoints Boesgaard as CFO - PDS Biotechnology announced the appointment of Lars Boesgaard as Chief Financial Officer, CFO, effective as of December 4, 2023. Boesgaard succeeds Matthew Hill, who resigned as PDS Biotech's CFO on November 21, 2023, effective December 1, 2023, to pursue other professional endeavors. Prior to joining PDS Biotech, Boesgaard served as CFO of AM-Pharma B.V. from September 2021 to August 2023.
FURY

Hot Stocks

07:24 EST Fury Gold Mines provides results for infill drilling at Hinge Target - Fury Gold Mines provides additional results from the 2023 infill drilling program at the Hinge Target at the high-grade Eau Claire gold project located in the Eeyou Istchee Territory in the James Bay region of Quebec. The Hinge Target infill program has increased confidence in the geological model and potential for expansion of the Eau Claire resource to the west. Drilling continues to intercept multiple zones of gold mineralization including 5.5 metres of 4.52g/t gold and 3.0m of 3.34g/t gold from 23EC-069; 1.0m of 20.20g/t gold and 3.5m of 3.51g/t gold from 23EC-070; 1.0m of 19.55g/t gold from 23EC-066; and 3.5m of 3.82g/t gold from 23EC-067. Results from an additional eleven drill holes are still being processed for the Hinge Target. "We are pleased to announce that we have completed approximately 19,000m within 31 holes drilled between the Hinge Target at the Eau Claire deposit and the Percival Prospect, 14km to the east. We not only exceeded our planned 15,000m of drilling for this year's program, but we also came in under budget," commented Tim Clark, CEO of Fury, "Going forward, we have 16 more drill holes pending results and we reiterate that Fury remains one of the best positioned junior explorers in the sector."
NTRB

Hot Stocks

07:23 EST Nutriband launches Heating and Cooling Kinesiology Tape - Nutriband announced the launch of its new Heating and Cooling Kinesiology Tape as part of its Active Intelligence Brand portfolio. AI Tape Heating and Cooling provides all of the stretch, support, and benefits of traditional kinesiology tape, plus pain-relieving ingredients that provide both heating and cooling sensation for the temporary relief of minor aches and pains of muscles and joints. The Heating and Cooling product marks AI Tape's second product launched this year. All AI Tape products are manufactured in the USA at Nutriband's facility in Cherryville, North Carolina.
AAL

Hot Stocks

07:22 EST American Airlines signs first carbon removal purchase agreement with Graphyte - American Airlines will be the inaugural customer of Graphyte, a carbon removal startup backed by Breakthrough Energy Ventures, with the purchase of 10,000 tons of permanent carbon removal to be delivered in early 2025. Graphyte's Carbon Casting process leverages readily available biomass, processing and monitoring to make carbon dioxide removal quantifiable and permanent. American has a long-term goal to reach net-zero emissions by 2050, and is investing in a variety of technologies to reduce its carbon footprint. With its purchase of carbon removal credits from Graphyte, American aims to accelerate and scale the CO2 removal market. This first commercial-scale deployment of Carbon Casting will take place at a Graphyte facility in Pine Bluff, Arkansas.
PEV

Hot Stocks

07:21 EST Phoenix Motor, Rayz Technologies establish cooperation for autonomous vehicles - Phoenix Motor has reached an agreement with Rayz Technologies to pre-install Rayz Technologies' flagship mass-production LiDAR sensors in its next generation electric vehicles. The company's future product lines, including electric pickup trucks, buses, trucks, and other models will be fully equipped with Rayz new generation of LIDAR Osprey H2. Rayz Technologies high performance LiDAR sensor Osprey H2 is a mid-to-long-range, cost-effective automotive-grade LiDAR specially designed for the ADAS pre-installed mass production market and high-level intelligent driving.
DPRO

Hot Stocks

07:19 EST Draganfly's Heavy Lift Drone receives SFOC - Draganfly has received a Transport Canada Special Flight Operations Certificate for its Heavy Lift Drone to support advanced flight testing above 55lbs/25KG MTOW. This will allow highly specialized development of advanced delivery, industrial and defense applications. The Heavy Lift Flight Testing SFOC allows Draganfly to conduct these specialized and advanced operations utilizing the Heavy Lift within an approved flight test area, enabling the Company to initiate direct application and use-case testing. This development also allows Draganfly to enhance and optimize highly specialized operational and maintenance manuals and Standard Operating Procedures for a variety of conditions and scenarios.
GOLD

Hot Stocks

07:15 EST Xali Gold signs agreement with Barrick Gold in Peru - Xali Gold has signed an Option Agreement with Barrick Gold Corporation on the Tres Marias Property located in southern Peru. As per the Agreement, Barrick must pay Xali Gold $175,000 over a 5-year period and spend $500,000 in exploration work to earn 100% of the Property subject to Xali Gold retaining a 1.5% Net Smelter Return Royalty. Barrick retains the right to purchase 1% of the NSR Royalty, for a single one-time payment of $750,000, which would decrease the NSR Royalty from 1.5% to 0.5%. Tres Marias is located within an emerging epithermal gold, silver and polymetallic belt of southern Peru which includes several new mines and discoveries by Barrick, Minas Buenaventura, Gold Fields, Aruntani and Bear Creek and is considered one of the fastest growing precious metal mining districts in Peru. A northwesterly trend extends over 200 kilometers and a northeasterly trend covers approximately 60 km so far. Xali Gold holds a 100% interest in the Tres Marias Property and has identified many exploration targets for both gold and silver mineralization. Three veins have been found to contain high grades of silver with lead and zinc mineralization. Anomalous gold levels also occur in high sulphidation style alteration surrounding the veins and are associated with rhyolite domes. Historic mine workings and remnants of a small smelting furnace are believed to date back to the time of Spanish explorers in the late 1800's. The low sulfidation system comprises three vein systems within a northwest trending system traced to date over 700 metres in strike length. The three main known veins show a fan-like outcrop pattern converging on the Casua claim, making it a highly prospective exploration target. The most prolific vein found to date, the Pataquena, has seen only minimal near surface exploitation and exploration. It has now been traced for over one kilometer and remains open to the north and south.
RLYB

Hot Stocks

07:14 EST Rallybio announces preliminary data from multiple dose cohort of RLYB212 trial - Rallybio announced preliminary data from the completed multiple dose cohort of the Phase 1 safety and pharmacokinetics, or PK, study for RLYB212, an anti-HPA-1a monoclonal antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia. The Phase 1 multiple dose cohort for RLYB212 was initiated in the first quarter of 2023 to evaluate the safety and PK of subcutaneous, or SC, RLYB212 based on repeat dosing over 12 weeks. Eight HPA-1a negative subjects participated in the multiple dose cohort; six subjects received RLYB212 every 2 weeks and 2 received placebo every 2 weeks. The preliminary data demonstrated that multiple dose PK were consistent both within and between subjects. The preliminary data and the Company's clinical pharmacology modeling predictions support a once monthly dosing regimen for the planned Phase 2 study. Consistent with previously reported data, RLYB212 was observed to be generally well-tolerated with no reports of injection site reactions or serious adverse events. Rallybio also announced that the RLYB212 toxicology package to support the planned Phase 2 and Phase 3 studies, including the maternal fetal toxicology program, is complete. Rallybio expects to submit both the RLYB212 clinical pharmacology model and the Phase 2 dosing approach, including supportive clinical and nonclinical data, to a peer reviewed journal in 2024.
ATHA

Hot Stocks

07:12 EST Athira Pharma to present data from preclinical studies of ATH-1105 - Athira Pharma announced that a symposium presentation highlighting data from preclinical studies of ATH-1105 as a potential treatment candidate for amyotrophic lateral sclerosis will be delivered at the upcoming Motor Neurone Disease Association 34th International Symposium on ALS/MND, to be held December 6 - 8, 2023 in Basel, Switzerland. We look forward to the presentation of these data, which highlight the potential of ATH-1105 as a treatment for ALS and add to the growing body of scientific and clinical data that support the potential benefits of our small molecule therapeutic candidates targeting the neurotrophic HGF system as novel treatments for neurodegenerative diseases," stated Mark Litton, Ph.D., President and Chief Executive Officer of Athira. "These data, which include preclinical data showing prolonged survival and demonstrating consistent improvements in motor function, nerve function, biomarkers and nerve morphology in a transgenic mouse model of ALS, strongly support confidence in our plans to advance this program into human clinical studies in the first half of 2024."
OFIX ENOV

Hot Stocks

07:11 EST Orthofix names Massimo Calafiore President and CEO - Orthofix Medical (OFIX) announced that Massimo Calafiore has been named incoming President and Chief Executive Officer. Calafiore is currently Chief Executive Officer of LimaCorporate, a global orthopedics company, and his appointment to Orthofix is expected to be effective in early 2024, following the completion of LimaCorporate's previously announced acquisition by Enovis Corporation (ENOV). At that time, Mr. Calafiore is also expected to join Orthofix's Board of Directors.
XTRAF

Hot Stocks

07:10 EST Xtract One selected by Community Health Network for weapons detection services - Xtract One Technologies announced its SmartGateway System has been selected to protect key hospital locations in the Indianapolis-based Community Health Network. The system underwent a rigorous and successful 30-day pilot program at Community Hospital East, during which the technology demonstrated its effectiveness in detecting weapons. In collaboration with their partner, Indiana-based CK2 Technologies, Community has chosen Xtract One's SmartGateway system to ensure weapons are not brought into hospitals within their network, and to ensure a safe and comforting environment for all patients, staff, and visitors. This solution unobtrusively scans patrons for guns, knives, and other prohibited items as they enter the facility, using AI-powered sensors to detect threats without invading patrons' sense of privacy and comfort. With Xtract One, Community will be able to build upon their facilities' existing security measures, and ensure they deliver quick and safe entry experiences for all employees, patients, and visitors entering their hospitals. "In the past year alone, various regions across the country have seen nursing strikes and demands by medical personnel for a safer workplace environment. Healthcare professionals have expressed that they no longer feel safe at work, and are choosing to leave the profession," said Peter Evans, CEO of Xtract One. "With the SmartGateway, we can help healthcare facilities like the Community Health Network create a warm, welcoming healthcare environment across their facilities that both fits their aesthetic, and increases the safety for employees, patients, and visitors."
ROIV IMVT

Hot Stocks

07:10 EST Roivant notes Immunovant data from Phase 1 IMVT-1402 trial - Immunovant announced initial data from 600 mg MAD cohort of a Phase 1 clinical trial of IMVT-1402 in healthy adults. The results show that four subcutaneously administered doses of 600 mg produced a mean IgG reduction similar to high dose batoclimab, but with minimal changes in albumin and LDL-C similar to those in placebo, confirming the potential of IMVT-1402 as a best-in-class neonatal fragment crystallizable receptor inhibitor. The Phase 1 clinical trial is a randomized, double-blind, placebo-controlled ascending dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IMVT-1402 in healthy adults. Four once-weekly SC injections of 600 mg IMVT-1402 reduced total IgG level by a mean of 74%, a potency that is similar to batoclimab at 680 mg that reduced IgG by 76% after 4 weekly doses. In disease settings where batoclimab was administered continuously, a reduction of 80% was observed at steady state after about 6-8 weeks. We believe steady state IgG reduction with IMVT-1402 will match this result and timing. Across all doses evaluated, treatments with IMVT-1402 were generally well tolerated with only mild or moderate treatment-emergent adverse events observed. Serum albumin and LDL-C at Day 29 did not show a significant decrease or increase, respectively, from baseline.
PRAX

Hot Stocks

07:08 EST Praxis Precision to showcase pipeline of epilepsy programs at AES meeting - Praxis Precision Medicines announced that it will deliver presentations on its epilepsy programs at the following upcoming meetings in Orlando, Florida. Presentations at the American Epilepsy Society, AES, Annual Meeting, as well as related scientific and patient advocacy meetings, will cover new patient data, updates on clinical progress and new paradigms for developing epilepsy therapies. "It's an incredibly exciting time for Praxis and our epilepsy portfolio, as we share updates from first-in-patient and Phase 2 studies for elsunersen (PRAX-222), PRAX-562 and PRAX-628," said Marcio Souza, president and chief executive officer of Praxis. "We look forward to presenting data spanning our Solidus and Cerebrum platforms at AES and related meetings in Florida, with presentations also set to highlight novel approaches to define efficient preclinical models and sensitive biomarkers for accelerating drug development for the patient populations we are seeking to serve. Our epilepsy programs have the potential to significantly impact the lives of patients and their families, and we are grateful for the opportunity to discuss these programs with the epilepsy community at multiple important meetings this week."
IMVT

Hot Stocks

07:07 EST Immunovant announces results from 600 mg MAD cohort of Phase 1 IMVT-1402 trial - Immunovant announced initial data from 600 mg MAD cohort of a Phase 1 clinical trial of IMVT-1402 in healthy adults. The results show that four subcutaneously administered doses of 600 mg produced a mean IgG reduction similar to high dose batoclimab, but with minimal changes in albumin and LDL-C similar to those in placebo, confirming the potential of IMVT-1402 as a best-in-class neonatal fragment crystallizable receptor inhibitor. The Phase 1 clinical trial is a randomized, double-blind, placebo-controlled ascending dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IMVT-1402 in healthy adults. Four once-weekly SC injections of 600 mg IMVT-1402 reduced total IgG level by a mean of 74%, a potency that is similar to batoclimab at 680 mg that reduced IgG by 76% after 4 weekly doses. In disease settings where batoclimab was administered continuously, a reduction of 80% was observed at steady state after about 6-8 weeks. We believe steady state IgG reduction with IMVT-1402 will match this result and timing. Across all doses evaluated, treatments with IMVT-1402 were generally well tolerated with only mild or moderate treatment-emergent adverse events observed. Serum albumin and LDL-C at Day 29 did not show a significant decrease or increase, respectively, from baseline.
ORN NR

Hot Stocks

07:07 EST Orion Group names Chip Earle as General Counsel - Orion Group (ORN) announced the appointment of Edward Chipman Earle as Executive Vice President, General Counsel, Chief Administrative Officer, Chief Compliance Officer and Corporate Secretary, effective November 27th. Earle will succeed Executive Vice President Peter Buchler, who is retiring from Orion after 15 years of service. Earle joins Orion from Newpark Resources (NR), a service provider to the industrial and energy sectors, where he was Vice President - General Counsel, Chief Administrative Officer, Chief Compliance Officer, and Corporate Secretary.
SOPH

Hot Stocks

07:06 EST Sophia Genetics expands relationship with largest health center in Italy - Sophia Genetics announced the expansion of its relationship with the Citta della Salute e della Scienza di Torino located in Turin, Italy. The hospital, which used Sophia Genetics after a public tender in 2021 to optimize workflows and support research in the areas of hereditary cancer, neurological disorders, solid tumors, hematology and rare disease, will further expand its usage of the SOPHiA DDM Platform to support research on homologous recombination repair biomarkers that indicate treatment options for ovarian, prostate, breast and pancreatic cancers.
ELBM

Hot Stocks

07:06 EST Electra Battery teams with Rock Tech Lithium on recycled lithium development - Electra Battery Materials announced the signing of a memorandum of understanding with Rock Tech Lithium for the development of a partnership to supply recycled lithium from Electra's Ontario battery recycling operations for upgrading to battery-grade lithium chemicals in Rock Tech's lithium refineries. The companies will leverage their processing expertise to develop a comprehensive, fully sustainable closed-loop service offering for the recycling of lithium-ion battery manufacturing scrap, end-of-life batteries and black mass.
AMLI

Hot Stocks

07:05 EST American Lithium files semi-detailed environmental impact assessment study - American Lithium announces that it has now completed and submitted the Semi-Detailed Environmental Impact Assessment Study for the Falchani Lithium Project in Southern Peru to the Ministry of Energy and Mines. Simon Clarke, CEO of American Lithium states, "This is another major milestone for American Lithium. The EIA process was launched during the prior Government at a difficult time for permitting in Peru and it is a testament to the hard work of our Peru team that we were able to advance the Falchani Project in such a material way. I would also acknowledge the support of the new authorities in Peru in helping us fast-track this process with the common goal of seeing lithium production in the country as quickly as reasonably possible. With this approval, we will now be able to complete our PFS and move rapidly into the mine permitting process."
GOOS

Hot Stocks

07:05 EST Canada Goose acquires operating assets of Paola Confectii Manufacturing - Canada Goose announced the acquisition of the operating assets of Paola Confectii Manufacturing. Building upon our existing network of seven facilities across Canada, this acquisition marks the company's first European facility, and supports our strategic growth plan, specifically expanding existing categories and increasing year-round relevance. Based in Romania, Paola Confectii has been a trusted partner in manufacturing luxury knitwear for Canada Goose since its launch in 2017, producing a range of best-selling styles including the HyBridge Knit Jacket. Knitwear is one of the leading segments of our growing Apparel category, which exceeded $70M in annual sales in fiscal 2023. This closer partnership is expected to enhance product margins and supply control, while deepening in-house product expertise.
GIB

Hot Stocks

07:05 EST CGI Inc.'s CGI Inc. forms IT joint venture with All In Solutions - CGI Inc.'s wholly-owned U.S. operating subsidiary CGI Federal announced its partnership with All In Solutions, a Service Disabled Veteran and Woman Owned Small Business, in a mentor-protege agreement to form Adcredo IT Solutions. The joint venture aims to leverage the organizations' know how to deliver mission-focused IT solutions on application and business consulting services that support federal civilian and defense missions. Adcredo leverages complex system integration and organizational change management experience, including CGI's multi-year transformation of financial management business processes at various administrations throughout the VA, coupled with managed services, AI, and data analytics capabilities to align with organizations' modernization strategies.
MDVL

Hot Stocks

07:05 EST Medavail announces agreement with St. Thomas Community Health Centers - MedAvail announced that it has entered into an agreement with New Orleans-based St. Thomas Community Health Centers for the deployment of two M4 MedCenter kiosks. St. Thomas operates eight Federally Qualified Health Centers, providing affordable health care to underserved communities across the New Orleans metropolitan area. "We are very excited to announce this new agreement with St. Thomas, building upon our existing infrastructure in the New Orleans area and growing our presence in the FQHC partner channel, where we see significant long-term growth opportunities," stated Mark Doerr, Chief Executive Officer of MedAvail. "We look forward to a long and mutually beneficial partnership."
SKYE

Hot Stocks

07:05 EST Skye Bioscience treats first patient in blaucoma Phase 2 study of SBI-100 - Skye Bioscience has treated the first patient in its Phase 2 clinical trial evaluating SBI-100 Ophthalmic Emulsion's ability to lower intraocular pressure, safety and relevant biomarkers, in patients with primary open-angle glaucoma or ocular hypertension. SBI-100 OE is a synthetic prodrug of tetrahydrocannabinol that is able to bind and activate CB1 receptors in key ocular tissues. "Skye's clinical pipeline targets the endocannabinoid system, which has seen growing development and M&A attention. We are advancing the next generation of investigational drugs targeting the endocannabinoid system's CB1 receptor," said Punit Dhillon, Skye's CEO and Chairman. "Key opinion leaders have indicated that there is a need for an alternative class of glaucoma medicine to serve patients that fail approved treatments and that potentially offers an improved safety profile. SBI-100 OE represents an opportunity to develop a first-in-class alternative with differentiated therapeutic characteristics. Following our encouraging Phase 1 results, we look forward to assessing initial Phase 2 IOP results in Q1 2024."
HON TT

Hot Stocks

07:04 EST Honeywell names Michael Lamach to Board of Directors - Honeywell (HON) announced that its board of directors has elected Michael Lamach, former executive chair of Trane Technologies (TT), to its board of directors as an independent director and Audit Committee member, effective December 1, 2023.
AMLX

Hot Stocks

07:03 EST Amylyx appoints Camille Bedrosian as chief medical officer - Amylyx announced the appointment of Camille Bedrosian as chief medical officer, or CMO. In this role, Bedrosian will lead global functions in medical affairs, regulatory, safety and pharmacovigilance, biometrics, clinical development, and clinical operations. Bedrosian brings nearly 30 years of experience. Amylyx' current CMO, Patrick Yeramian will stay on as an advisor through the end of the year and will then transition into retirement, as announced in December 2022.
GXO

Hot Stocks

07:03 EST GXO Logistics adds returns to extended agreement with Amer Sports - GXO Logistics announced that it has extended its agreement with, and added returns processing to, its partnership with Amer Sports, a leading sporting goods manufacturer whose brands include Salomon, Wilson, Arc'teryx and Atomic. "We are pleased to extend our longstanding and valued partnership with Amer Sports and to expand the scope of our services to include reverse logistics," said Rui Marques, Managing Director, France, GXO. "Since 2015, we've been leveraging our industry-leading technology and expertise to help Amer Sports continuously improve its logistics, and now we're excited to apply our reverse logistics expertise to returns from retail stores, B2B and e-commerce. With our significant focus on continuous improvement in our customer solutions, we're looking forward to more opportunities to use technology to support our team members on site and continue enhancing their working environment."
CARM

Hot Stocks

07:03 EST Carisma Therapeutics: FDA clears IND application for CT-0525 - Carisma Therapeutics announced the clearance of its Investigational New Drug application by the U.S. FDA for CT-0525, an ex vivo gene-modified autologous chimeric antigen receptor-monocyte cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2. Having received a Study May Proceed notification from the FDA, Carisma expects to initiate a Phase 1 study in the coming months and to treat the first patient in the first half of 2024.
PYXS KNTE

Hot Stocks

07:02 EST Pyxis Oncology announces appointment of Kobayashi as CMO - Pyxis Oncology (PYXS) announced the appointment of Ken Kobayashi, M.D., F.A.C.P, as Chief Medical Officer, CMO, effective November 27, 2023. Dr. Kobayashi brings extensive leadership experience in oncology clinical development and regulatory affairs. As CMO, Dr. Kobayashi will lead the Company's clinical and regulatory operations, drive strategic growth, and play a key role in advancing Pyxis Oncology's clinical pipeline. Most recently, Kobayashi served as Senior Vice President, Clinical Development at Kinnate Biopharma (KNTE).
GTLS

Hot Stocks

07:02 EST Chart Industries introduces medium-term financial targets through 2026 - Chart Industries is hosting an Investor Day, today, November 28, 2023, at 8:00am ET to present their view of Chart Industries strategic priorities, growth strategy, and three-year financial outlook. During today's investor day event, the Chart Industries management team will discuss how the business is poised to deliver profitable growth and free cash flow generation through a cycle. Further, the team will provide insights on how it can deliver on its record backlog, which is tied to secular growth trends such as sustainability and energy security, to drive profitable growth. Chart will introduce medium-term financial targets through 2026, including: Mid-teens Organic Revenue growth through 2026; Reported Gross Profit Margin of mid-30%'s in 2026; Double-digit Adjusted Diluted EPS growth CAGR of mid-40%'s; 95-100% Free Cash Flow Conversion. The Company also will be providing an update regarding commercial and cost synergy numbers year-to-date and expected incremental cost synergies for 2024 given further visibility into savings opportunities.
EBS

Hot Stocks

07:02 EST Emergent BioSolutions receives $75M anthrax vaccine contract from BARDA - Emergent BioSolutions announced that the Biomedical Advanced Research and Development Authority - BARDA - within the Administration for Strategic Preparedness and Response at the Department of Health and Human Services has awarded a $75M option to Emergent's existing contract for the acquisition of newly licensed anthrax vaccine Cyfendus. Deliveries are expected to begin this calendar year and be complete by the end of 1Q24. The Cyfendus vaccine was approved by the FDA in July 2023 as a two-dose anthrax vaccine for post-exposure prophylaxis use in individuals 18 years of age and older. In 2016, BARDA and Emergent extended their partnership to support clinical development and manufacturing efforts for the AV7909 vaccine, including a Phase 3 trial to demonstrate safety and efficacy, working toward the goal of eventual FDA licensure. In April 2022, Emergent submitted the Biologics License Application to the FDA for review, leading to approval and licensure in July 2023.
MRK

Hot Stocks

06:49 EST Merck's pneumococcal vaccine shows superior immunogenicity - Merck announced results from STRIDE-3, a Phase 3 trial evaluating V116, the company's investigational pneumococcal conjugate vaccine designed to protect adults. The trial evaluated the immunogenicity, tolerability and safety of V116 compared to PCV20 - pneumococcal 20-valent conjugate vaccine - in adults who had not previously received a pneumococcal vaccine. In adults 50 years of age and older, V116 elicited non-inferior immune responses compared to PCV20 for all 10 serotypes common to both vaccines. Immune responses elicited by V116 were superior for 10 of 11 serotypes included in V116 but not in PCV20 as measured by OPA GMTs at Day 30 and the proportions of patients with a greater than or equal to four-fold increase in OPA from Day 1 to Day 30. In adults 18 to 49 years of age, V116 elicited non-inferior immune responses vs. adults 50 to 64 years of age. Across both cohorts, V116 had a safety profile comparable to PCV20. Serotypes covered by V116 are responsible for approximately 83% of invasive pneumococcal disease in individuals 65 years of age and older. If approved, V116 would be the first pneumococcal conjugate vaccine specifically designed for adults.
DOW

Hot Stocks

06:42 EST Dow Inc. board approves final investment decision for Path2Zero project - Dow Inc. announced that its board of directors has declared Final Investment Decision on the company's Fort Saskatchewan Path2Zero investment to build the world's first net-zeroi Scope 1 and 2 emissions integrated ethylene cracker and derivatives facility in Alberta, Canada. The $6.5B project, excluding governmental incentives and subsidies, includes building a new ethylene cracker and increasing polyethylene capacity by 2 million MTA as well as retrofitting the site's existing cracker to net-zero Scope 1 and 2 emissions. The investment is expected to deliver $1B of EBITDA growth per year at full run rates over the economic cycle while decarbonizing 20% of Dow's global ethylene capacity. This new capacity will enable Dow to capture growing customer demand in high-value markets, such as packaging, infrastructure and hygiene, among others, with potential additional value captured from commercializing low and zero-emissions products. The project builds on Dow's expertise in successfully implementing large projects, such as its TX-9 cracker in Freeport, Texas, which has delivered more than 15% return on invested capital since its 2017 start-up through best-in-class capital intensity, conversion cost, and low emissions intensity. The board's approval enables the Company to begin construction in 2024. Capacity additions are expected to come online in phases, with the first phase starting up in 2027, adding approximately 1,285 KTAiv of ethylene and polyethylene capacity, and the second phase starting up in 2029, adding an additional approximately 600 KTA of capacity. To achieve net-zero Scope 1 and 2 emissions, the Fort Saskatchewan Path2Zero project will deploy Linde's air separation and autothermal reformer technology to convert the site's cracker off-gas to hydrogen, which will be used as a clean fuel to supply the site's furnaces. In addition, carbon dioxide emissions will be captured and stored, reducing existing emissions by approximately 1M MTA of CO2e while abating all emissions from the addition of the site's new capacity.
RNA BMY

Hot Stocks

06:35 EST Avidity Biosciences expands cardiovascular collaboration with Bristol Myers - Avidity Biosciences (RNA) announced a global licensing and research collaboration with Bristol Myers Squibb (BMY) focused on the discovery, development and commercialization of multiple cardiovascular targets with potential cumulative payments of up to $2.3B. Antibody Oligonucleotide Conjugates, or AOCs, are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. This strategic collaboration broadens the reach of AOCs through the expansion of the existing relationship with Bristol Myers Squibb. Avidity continues to advance its internal research and development programs in rare cardiac indications. Under the terms of the agreement, Avidity will receive $100M upfront, which includes a $60M cash payment as well as the purchase of approximately $40M of Avidity common stock at a purchase price of $7.88 per share. Avidity is also eligible to receive up to approximately $1.35B in research and development milestone payments, up to approximately $825M in commercial milestone payments, and tiered royalties up to low double-digits on net sales. Bristol Myers Squibb will fund all future clinical development, regulatory and commercialization activities coming from this collaboration.
SQ

Hot Stocks

06:30 EST Block reports Black Friday and Cyber Monday results of Afterpay platform - Block reported that over the Black Friday and Cyber Monday weekend, its Afterpay payment platform set a new record, along with Block, with 70M transactions, up 14% from last year. Consumers continued to display diverse shopping habits as in-person shopping increased 15%, while online cart sizes were 3.9X higher than in-person. 9% more businesses leveraged the power of omnichannel by attracting buyers both in-person and online. Buy Now, Pay Later transactions through Afterpay increased 19%, and Square sellers saw their Afterpay transactions grow 47%. The largest Afterpay item categories outside of fashion and beauty were hardware, home and garden, arts and entertainment, office supplies, and electronics. Usage for the Afterpay app was up 16%.
BGNE

Hot Stocks

06:13 EST BeiGene to present new data on hematology portfolio and pipeline - BeiGene is presenting new data across a range of assets and blood cancers at the upcoming 65th American Society of Hematology Annual Meeting and Exposition December 9-12 in San Diego. BeiGene has 24 abstracts accepted at ASH, with three abstracts scheduled for oral presentations. Brukinsa continues to show sustained PFS benefit versus ibrutinib in the global Phase 3 ALPINE trial of patients with R/R CLL/SLL with this longer follow up. Durable PFS was observed across major subgroups. Overall safety and tolerability profile was consistent with previous ALPINE analyses, including persistently lower rates of cardiovascular events reported with BRUKINSA. Based on these results, BRUKINSA continues to be a more efficacious and better-tolerated treatment than ibrutinib for patients with R/R CLL/SLL. Data from Waldenstrom Macroglobulinemia patients who switched to receive BRUKINSA on a long-term extension study demonstrate generally improved safety and deepening of responses with the switch to BRUKINSA. In an ongoing Phase 2 study, data suggest that for patients intolerant of acalabrutinib, switching to BRUKINSA leads to better tolerance while maintaining or deepening response. Patients with treatment-naive CLL/SLL were treated with sonrotoclax in combination with BRUKINSA. The combination was observed to be well tolerated; no cases of tumor lysis syndrome were observed. There was a 100% response rate. Sonrotoclax has also been well tolerated with high response rates as monotherapy in a Phase 1 study in patients with R/R marginal zone lymphoma. Sonrotoclax was also evaluated in combination with dexamethasone in patients with R/R multiple myeloma. The combination is safe and efficacious, with the majority of patients across all dose levels achieving clinical response, including deep responses.
NVS

Hot Stocks

06:11 EST Novartis upgrades mid-term sales guidance to 5% CAGR for 2022-27 - Novartis executives are meeting investors and analysts today at an event in London, U.K., to showcase the company's "pure play" innovative medicines strategy and focused Research and Development pipeline, the company announced. "Novartis has now completed its transformation into a 'pure-play' innovative medicines company, delivering robust increases in core margin and free cash flow, while also continuing strong operational performance. We remain committed to executing our focused strategy, and creating significant shareholder value in the short-, mid-, and long-term as illustrated by our upgraded mid-term sales guidance to 5% CAGR and ~40%+ core operating income margin. Our pipeline is focused on delivering high value assets across our four core therapeutic areas and fully realizing the potential of our advanced technology platforms, which could unlock future substantial growth," said Vas Narasimhan M.D., CEO of Novartis. "The company continues to make significant progress in improving the performance of R&D through active prioritization of the pipeline to focus on high-value assets, and driving operational excellence within the organization. This has enabled increased resourcing for priority projects and strengthening functional capabilities. Across Biomedical Research and Development, resources have been streamlined to maximize focus and enhance competencies. The strong, streamlined portfolio now comprises 103 projects including 46 NMEs, with up to 15 key submissions for regulatory approval expected in the 2024-2027 timeframe, each targeted to address major unmet needs and with significant sales potential," the company stated. Mid-term sales guidance has been upgraded to 5% CAGR 2022-27, with core operating income margin of about 40%-plus by 2027, driven by continued strong momentum of key growth drivers and "confidence to grow mid-single digit longer-term based on the foundational strength of de-risked existing brands and pipeline assets," the company added.
NVAX

Hot Stocks

06:09 EST Novavax announces NVX-CoV2601 granted emergency use listing by WHO - Novavax announced that Nuvaxovid XBB.1.5 COVID-19 Vaccine, or NVX-CoV2601, has been granted Emergency Use Listing, or EUL, by the World Health Organization, or WHO, for active immunization to prevent COVID-19 in individuals aged 12 and older. The EUL assists WHO member states in assessing vaccines with the aim of expediting availability and enables the WHO's 194 member states to expedite regulatory approvals to import and administer the vaccine.
TRP

Hot Stocks

06:08 EST TC Energy provides outlook for 2023 and 2024 - TC Energy now expects comparable EBITDA to be approximately 8% higher than 2022. Provides expected comparable EBITDA growth outlook of 5%-7% from 2023 to 2024, excluding any potential impact of its asset divestiture program, and prior to giving effect to the spinoff, expected to take place in the second half of 2024. TC Energy also expects to advance an incremental $3B of asset sales next year and reaffirms its commitments to achieve its 4.75x debt-to-EBITDA upper limit by the end of 2024 and maintain its targeted $6B-$7B annual net capital spending in 2025 and beyond. The company will further high-grade its capital allocation toward low-risk opportunities that strengthen its core businesses, including developing commercial constructs with risk mitigations and appropriately sharing cost, schedule and regulatory risk. Expects to deliver approximately 7% comparable EBITDA growth from its natural gas and power businesses between 2023 and 2026.
BNS

Hot Stocks

06:07 EST Scotiabank reports Q4 net interest margin 2.16% vs. 2.18% last year - Reports Q4 return on equity of 7.2% vs. 11.9% last year.
WRN RIO

Hot Stocks

06:06 EST Western Copper announces further C$6M investment in Rio Tinto Canada - Western Copper (WRN) announced a further C$6M investment and the entry into an amended and restated investor rights agreement by Rio Tinto Canada (RIO), to continue to advance the company's Casino Project in the Yukon. Rio Tinto has agreed to subscribe for and purchase 3,468,208 common shares at a price of C$1.73 per share for aggregate gross proceeds of approximately C$6M, resulting in Rio Tinto's ownership increasing to approximately 9.7% of Western's outstanding common shares. Western remains the sole owner of the Casino Project and will continue to be the operator. The company will use the proceeds of this further investment to fund specific areas of study, specifically around providing infrastructure for the Casino Project, and streamlining the regulatory process, with the aim of progressing through permitting to a development phase for the Casino Project.
CCI

Hot Stocks

06:04 EST Crown Castle names Chris Levendos as COO for Towers and Fiber - Crown Castle announced that, following a months long external and internal search, Chris Levendos has been appointed as Executive Vice President and COO to lead both of the company's operating segments, Towers and Fiber. In addition to his previous role as Executive Vice President and COO - Fiber, Levendos has been acting as interim Executive Vice President and COO - Towers since October 1, 2023.
OGI

Hot Stocks

06:03 EST Organigram ncreases investment in Phylos after milestone achievement - Organigram announced that Phylos Bioscience, a U.S. cannabis genetics company and provider of production ready seeds, has achieved the first milestone under the loan agreement entered into in May 2023 and has closed the second tranche under the Loan Agreement with Organigram advancing $2.75M to Phylos. This second tranche follows the initial tranche of $3.25M advanced in May 2023 for a total of $6M in senior secured convertible loans currently outstanding. After funding the second tranche, $6M of principal is outstanding and the Loan Agreement contains a commitment to fund up to an additional $2M no later than May 2025, upon the completion of certain milestones. The Convertible Loans will accrue paid-in-kind interest at a rate of U.S. Prime + 3.5% with an overall cap of 11% subject to certain conditions. The Convertible Loans' principal and payment-in-kind interest outstanding are convertible into common share equity of Phylos under certain circumstances.
GOOG GOOGL

Hot Stocks

05:58 EST Google investigating reports of issue impacting 'limited subset' of Drive users - Google said on its Community forums that it's investigating an issue that has caused Drive files to go missing. Google did not disclose the reason for the issue, but says that a "limited subset of Drive for desktop users" are seeing the problem and that it is related to versions 84.0.0.0 through 84.0.4.0, which recently rolled out. Google is still "investigating" the problem." Reference Link
ARGX

Hot Stocks

05:30 EST Argenx announces ADVANCE-SC study did mot meet primary, secondary endpoints - Argenx announced topline results from the ADVANCE-SC study evaluating Vyvgart Hytrulo in adults with primary immune thrombocytopenia, or ITP. The study did not meet the primary endpoint of a sustained platelet count response in chronic ITP patients. Additional analyses of the dataset are ongoing and the full results will be presented at an upcoming medical meeting and in a peer-reviewed publication. ADVANCE-SC is the second of two registrational trials conducted as part of the ongoing ITP development program for Vyvgart and enrolled 207 adult patients with chronic and persistent ITP. Patients were heavily pre-treated and 75% of patients had received three or more prior ITP therapies. Primary endpoint was not met; 13.7% of treated patients demonstrated a sustained platelet count response compared to 16.2% of placebo patients. Secondary endpoints were not met, including additional endpoints on International Working Group, or IWG, responder status and mean platelet count change from baseline. Vyvgart Hytrulo was well-tolerated in ADVANCE-SC; the observed safety and tolerability profile was consistent with ADVANCE-IV and the confirmed safety profile of Vyvgart and Vyvgart Hytrulo. Results from the first study in the ITP registrational program, ADVANCE-IV, were reported in May 2022. The study met its primary and key platelet-derived secondary endpoints. ADVANCE-IV formed the basis of the regulatory submission for approval of Vyvgart IV for ITP in Japan, where a decision is expected in the first quarter of 2024. Vyvgart is currently being evaluated in 13 severe autoimmune diseases, including the registrational ADDRESS study for pemphigus from which topline results are expected around year-end 2023.
PLMI

Hot Stocks

05:17 EST Veea to become public through Plum Acquisition Corp. I combination - Veea, a digital transformation company, and Plum Acquisition Corp. I, a Cayman Islands exempted company formed as a special purpose acquisition company by Ursula Burns, Kanishka Roy and Mike Dinsdale, announced their entry into a definitive business combination agreement related to a proposed merger expected to result in Veea becoming a publicly traded company whose business, after the closing, assuming the occurrence thereof, will be the continued business of Veea. The transaction implies a total enterprise value of approximately $281M, prior to an anticipated $50M private financing by Veea, assuming certain redemptions of Plum public shares. The proposed business combination between Plum and Veea is structured as a merger between a wholly-owned subsidiary of Plum, on the one hand, and Veea, on the other, following which Plum, after transitioning out of the Cayman Islands and into the State of Delaware to become a Delaware corporation, will be renamed and will continue the business of Veea. The transaction consideration to be issued to Veea securityholders at the closing of the proposed business combination will consist of newly-issued Plum securities determined based on a pre-money equity value for Veea's outstanding equity securities and certain outstanding debt that will be converted into equity at the closing of approximately $194M, excluding any money raised by Veea in its current financing. In addition, following the closing of the business combination, holders of Veea capital stock as of immediately prior to the closing will have the contingent right to receive up to 4.5M additional shares of combined company common stock if certain trading-price based milestones of the combined company's common stock are achieved during the ten-year period following the closing, as set forth in the business combination agreement. Proceeds from the proposed business combination and financing transactions are expected to support the combined company in its business plans. Current equity holders of Veea are expected to own a majority of the outstanding capital stock of the combined company immediately after the closing and Veea will appoint a majority of the members of the board of directors of the combined company in accordance with the terms of the business combination agreement. The parties expect the business combination to be consummated during the first half of 2024, following satisfaction of certain closing conditions set forth in the business combination agreement, including, without limitation, approval by shareholders of Plum and stockholders of Veea, the effectiveness of a registration statement to be filed by Plum with the Securities and Exchange Commission in connection with the transaction, the expiration of any HSR Act waiting period and other customary closing conditions. The proposed business combination has, prior to the execution of the business combination agreement, been approved by the boards of directors of each of Veea and Plum.